

REFINITIV

DELTA REPORT

10-Q

ENZ - ENZO BIOCHEM INC

10-Q - OCTOBER 31, 2024 COMPARED TO 10-Q - APRIL 30, 2024

The following comparison report has been automatically generated

TOTAL DELTAS	985
--------------	-----

 CHANGES	121
---------------------------------------------------------------------------------------------	-----

 DELETIONS	471
-----------------------------------------------------------------------------------------------	-----

 ADDITIONS	393
-----------------------------------------------------------------------------------------------	-----

UNITED STATES
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

Mark one

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 30, 2024 October 31, 2024

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____

Commission File Number 001-09974

ENZO BIOCHEM, INC.

(Exact name of registrant as specified in its charter)

New York

13-2866202

(State or Other Jurisdiction of
Incorporation or Organization)

(IRS. Employer
Identification No.)

21 Executive Blvd. Farmingdale, New York

11735

(Address of Principal Executive office)

(Zip Code)

(631) 755-5500

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock \$0.01 par value	ENZ	The New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant has required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 45 of Regulation S-T (§232.405 of that chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company, or an emerging growth company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes ☐ No ☒

As of June 10, 2024 December 12, 2024, the Registrant had 51,457,660 52,244,074 shares of common stock outstanding.

ENZO BIOCHEM, INC.
FORM 10-Q
April 30, October 31, 2024
INDEX

<u>PART I - FINANCIAL INFORMATION</u>	
Item 1.	<u>Financial Statements</u> 1
	<u>Consolidated Balance Sheets – April 30, 2024 October 31, 2024 (unaudited) and July 31, 2023 July 31, 2024</u> 1
	<u>Consolidated Statements of Operations for the three and nine months ended April 30, 2024 October 31, 2024 and 2023 (unaudited)</u> 2
	<u>Consolidated Statements of Comprehensive Loss for the three and nine months ended April 30, 2024 October 31, 2024 and 2023 (unaudited)</u> 3
	<u>Consolidated Statements of Stockholders' Equity for the three and nine months ended April 30, 2024 October 31, 2024 and 2023 (unaudited)</u> 4
	<u>Consolidated Statements of Cash Flows for the nine three months ended April 30, 2024 October 31, 2024 and 2023 (unaudited)</u> 6 5
	<u>Notes to the Consolidated Financial Statements</u> 7 6
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> 25 21
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 32 25
Item 4.	<u>Controls and Procedures</u> 33 25
<u>PART II - OTHER INFORMATION</u>	
Item 1.	<u>Legal Proceedings</u> 34 26
Item 1A.	<u>Risk Factors</u> 34 26
Item 6.	<u>Exhibits</u> 34 26
	<u>Signatures</u>
	<u>Signatures</u> 35 27

PART I FINANCIAL INFORMATION
ITEM 1 FINANCIAL STATEMENTS
ENZO BIOCHEM, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

	April 30, 2024 (unaudited)	July 31, 2023	October 31, 2024 (unaudited)	July 31, 2024
ASSETS				
Current assets:				
Cash and cash equivalents	\$ 57,156	\$ 82,373	\$ 47,735	\$ 52,371
Cash in escrow			—	5,000
Accounts receivable, net	3,935	4,808	3,842	3,988
Inventories, net	7,324	7,939	6,391	6,832
Prepaid expenses and other current assets, including \$5,000 escrow at April 30, 2024 and \$1,000 restricted cash at July 31, 2023	7,321	3,336		
Prepaid expenses and other current assets			1,693	1,840
Total current assets	75,736	98,456	59,661	70,031
Property, plant, and equipment, net	12,638	13,086	12,495	12,367
Right-of-use assets	2,959	3,626	2,654	2,836
Other assets, including \$5,000 escrow at July 31, 2023	591	5,745		
Non-current assets of discontinued operations, net	1,545	967		
Other assets			481	530
Total assets	<u>\$ 93,469</u>	<u>\$ 121,880</u>	<u>\$ 75,291</u>	<u>\$ 85,764</u>
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:				
Accounts payable – trade	\$ 1,520	\$ 3,575	\$ 1,269	\$ 1,376
Dividend payable			5,324	—
Accrued liabilities	5,376	11,743	5,618	5,714
Current portion of operating lease liabilities	799	980	827	841
Current portion of long term debt	75	75		
Convertible debentures	3,609	2,514		
Other current liabilities			76	76
Current liabilities of discontinued operations, net	10,284	21,102	10,283	16,787
Total current liabilities	21,663	39,989	23,397	24,794

Operating lease liabilities, non-current	2,595	3,160	2,209	2,403
Long term debt, net	180	269	155	189
Non-current liabilities of discontinued operations, net			1,872	2,266
Total liabilities	<u>\$ 24,438</u>	<u>\$ 43,418</u>	<u>\$ 27,633</u>	<u>\$ 29,652</u>
Contingencies – see Note 13				
Stockholders' equity:				
Preferred Stock, \$.01 par value; authorized 25,000,000 shares; no shares issued or outstanding	—	—	—	—
Common Stock, \$.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 51,227,535 at April 30, 2024 and 49,997,631 at July 31, 2023	511	499		
Common Stock, \$.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 52,244,074 at October 31, 2024 and July 31, 2024			521	521
Additional paid-in capital	347,069	344,435	342,981	348,134
Accumulated deficit	(281,047)	(268,350)	(297,804)	(294,428)
Accumulated other comprehensive income	2,498	1,878	1,960	1,885
Total stockholders' equity	<u>69,031</u>	<u>78,462</u>	<u>47,658</u>	<u>56,112</u>
Total liabilities and stockholders' equity	<u>\$ 93,469</u>	<u>\$ 121,880</u>	<u>\$ 75,291</u>	<u>\$ 85,764</u>

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(unaudited)

(in thousands, except per share data)

	Three Months Ended April 30,		Nine Months Ended April 30,		Three Months Ended October 31,	
	2024	2023	2024	2023	2024	2023
Revenues	\$ 8,022	\$ 7,485	\$ 24,381	\$ 22,102	\$ 6,213	\$ 7,806
Operating costs and expenses:						
Operating costs and expenses, net:						
Cost of revenues	4,289	4,476	12,969	13,681	3,681	4,351
Cost of revenues – inventory provision					252	—
Research and development	605	884	2,035	2,708	562	849
Selling, general and administrative	4,479	6,212	16,550	17,078		
Legal and related expense, net	692	4,265	2,527	6,160		
Selling, general, and administrative Legal and related expenses					4,882	7,007
					458	1,075
Total operating costs and expenses	10,065	15,837	34,081	39,627	9,835	13,282
Operating loss	(2,043)	(8,352)	(9,700)	(17,525)	(3,622)	(5,476)
Other income (expense):						
Interest, net	726	(36)	2,595	99	620	977
Change in fair value of convertible debentures	(384)	-	(1,095)	-	—	(328)
Other	94	144	373	262	123	158
Foreign exchange (loss) gain	(524)	347	(842)	1,022		
Total other income (expense)	(88)	455	1,031	1,383		
Foreign exchange loss					(192)	(1,006)
Loss before income taxes	(2,131)	(7,897)	(8,669)	(16,142)	(3,071)	(5,675)
Income taxes	—	—	—	—	—	—
Net loss from continuing operations	\$ (2,131)	\$ (7,897)	\$ (8,669)	\$ (16,142)	\$ (3,071)	\$ (5,675)
Net loss from discontinued operations	(889)	(7,290)	(4,028)	(21,000)	(305)	(941)
Net loss	(3,020)	(15,187)	(12,697)	(37,142)	(3,376)	(6,616)

Net loss per common share – basic and diluted:						
Continuing operations	\$ (0.04)	\$ (0.16)	\$ (0.17)	\$ (0.33)	\$ (0.07)	\$ (0.11)
Discontinued operations	(0.02)	(0.15)	(0.08)	(0.43)	(0.00)	(0.02)
Total net loss per basic and diluted common share	<u>\$ (0.06)</u>	<u>\$ (0.31)</u>	<u>\$ (0.25)</u>	<u>\$ (0.76)</u>	<u>\$ (0.07)</u>	<u>\$ (0.13)</u>
Weighted average common shares outstanding:						
Basic and diluted	<u>51,214</u>	<u>49,384</u>	<u>50,629</u>	<u>48,944</u>		
Basic					<u>52,244</u>	<u>50,184</u>
Diluted					<u>52,244</u>	<u>50,184</u>

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)
(unaudited)
(in thousands)

	Three Months Ended April 30,		Nine Months Ended April 30,		Three Months Ended October 31,	
	2024	2023	2024	2023	2024	2023
Net loss	\$ (3,020)	\$ (15,187)	\$ (12,697)	\$ (37,142)	\$ (3,376)	\$ (6,616)
Other comprehensive (loss) income:						
Other comprehensive income:						
Foreign currency translation adjustments	452	(372)	620	(994)	75	868
Comprehensive loss	<u>\$ (2,568)</u>	<u>\$ (15,559)</u>	<u>\$ (12,077)</u>	<u>\$ (38,136)</u>	<u>\$ (3,301)</u>	<u>\$ (5,748)</u>

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Three Months Ended April 30, 2024 October 31, 2024 and 2023
(unaudited)
(in thousands, except share data)

	<i>Common Stock Shares Issued</i>	<i>Common Stock Amount</i>	<i>Additional Paid-in Capital</i>	<i>Accumulated Deficit</i>	<i>Accumulated Other Comprehensive Income</i>	<i>Total Stockholders' Equity</i>
Balance at January 31, 2024	50,489,771	\$ 504	\$ 346,252	\$ (278,027)	\$ 2,046	\$ 70,775
Net loss for the period ended April 30, 2024	—	—	—	(3,020)	—	(3,020)
Share-based compensation charges	—	—	207	—	—	207
Vested restricted and performance stock units issued	249,912	2	—	—	—	2
Issuance of common stock for employee 401(k) plan match	487,852	5	610	—	—	615
Foreign currency translation adjustments	—	—	—	—	452	452
Balance at April 30, 2024	<u>51,227,535</u>	<u>\$ 511</u>	<u>\$ 347,069</u>	<u>\$ (281,047)</u>	<u>\$ 2,498</u>	<u>\$ 69,031</u>
	<i>Common Stock Shares Issued</i>	<i>Common Stock Amount</i>	<i>Additional Paid-in Capital</i>	<i>Accumulated Deficit</i>	<i>Accumulated Other Comprehensive Income</i>	<i>Total Stockholders' Equity</i>
Balance at January 31, 2023	48,733,054	\$ 487	\$ 340,407	\$ (310,593)	\$ 2,529	\$ 32,830
Net loss for the period ended April 30, 2023	—	—	—	(15,187)	—	(15,187)
Share-based compensation charges	—	—	563	—	—	563
Vesting of restricted stock units	86,667	1	—	—	—	1
Exercise of stock options	6,667	—	14	—	—	14
Issuance of common stock for employee 401(k) plan match	843,100	8	1,071	—	—	1,079
Foreign currency translation adjustments	—	—	—	—	(372)	(372)
Balance at April 30, 2023	<u>49,669,488</u>	<u>\$ 496</u>	<u>\$ 342,055</u>	<u>\$ (325,780)</u>	<u>\$ 2,157</u>	<u>\$ 18,928</u>
	<i>Common Stock Shares Issued</i>	<i>Common Stock Amount</i>	<i>Additional Paid-in Capital</i>	<i>Accumulated Deficit</i>	<i>Accumulated Other Comprehensive Income</i>	<i>Total Stockholders' Equity</i>

Balance at July 31, 2024	<u>52,244,074</u>	<u>\$ 521</u>	<u>\$ 348,134</u>	<u>\$ (294,428)</u>	<u>\$ 1,885</u>	<u>\$ 56,112</u>
Net loss for the three months ended October 31, 2024	—	—	—	(3,376)	—	(3,376)
Cash dividend declared	—	—	(5,324)	—	—	(5,324)
Share-based compensation charges	—	—	171	—	—	171
Foreign currency translation adjustments	—	—	—	—	75	75
Balance at October 31, 2024	<u>52,244,074</u>	<u>\$ 521</u>	<u>\$ 342,981</u>	<u>\$ (297,804)</u>	<u>\$ 1,960</u>	<u>\$ 47,658</u>

	<i>Common Stock Shares Issued</i>	<i>Common Stock Amount</i>	<i>Additional Paid-in Capital</i>	<i>Accumulated Deficit</i>	<i>Accumulated Other Comprehensive Income</i>	<i>Total Stockholders' Equity</i>
Balance at July 31, 2023	49,997,631	\$ 499	\$ 344,435	\$ (268,350)	\$ 1,878	\$ 78,462
Net loss for the three months ended October 31, 2023	—	—	—	(6,616)	—	(6,616)
Vested restricted stock unit issuances	144,530	1	—	—	—	1
Common stock issued for Asset Purchase Agreement bonus payment	347,610	4	481	—	—	485
Share-based compensation charges	—	—	1,075	—	—	1,075
Foreign currency translation adjustments	—	—	—	—	868	868
Balance at October 31, 2023	<u>50,489,771</u>	<u>\$ 504</u>	<u>\$ 345,991</u>	<u>\$ (274,966)</u>	<u>\$ 2,746</u>	<u>\$ 74,275</u>

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
Nine Months Ended April 30, 2024 and 2023
(unaudited)
(in thousands, except share data)

	<i>Common Stock Shares Issued</i>	<i>Common Stock Amount</i>	<i>Additional Paid-in Capital</i>	<i>Accumulated Deficit</i>	<i>Accumulated Other Comprehensive Income</i>	<i>Total Stockholders' Equity</i>
Balance at July 31, 2023	49,997,631	\$ 499	\$ 344,435	\$ (268,350)	\$ 1,878	\$ 78,462
Net loss for the period ended April 30, 2024	—	—	—	(12,697)	—	(12,697)
Vested restricted and performance stock unit issued	394,442	4	—	—	—	4
Common stock issued for Asset Purchase Agreement bonus payment	347,610	3	481	—	—	484
Share-based compensation charges	—	—	1,543	—	—	1,543
Issuance of common stock for employee 401(k) plan match	487,852	5	610	—	—	615
Foreign currency translation adjustments	—	—	—	—	620	620
Balance at April 30, 2024	<u>51,227,535</u>	<u>\$ 511</u>	<u>\$ 347,069</u>	<u>\$ (281,047)</u>	<u>\$ 2,498</u>	<u>\$ 69,031</u>

	<i>Common Stock Shares Issued</i>	<i>Common Stock Amount</i>	<i>Additional Paid-in Capital</i>	<i>Accumulated Deficit</i>	<i>Accumulated Other Comprehensive Income</i>	<i>Total Stockholders' Equity</i>
Balance at July 31, 2022	48,720,454	\$ 487	\$ 339,462	\$ (288,638)	\$ 3,151	\$ 54,462
Net loss for the period ended April 30, 2023	—	—	—	(37,142)	—	(37,142)
Share-based compensation charges	—	—	1,508	—	—	1,508
Vesting of restricted stock units	86,667	1	—	—	—	1
Vesting of performance stock units	12,600	—	—	—	—	—
Exercise of stock options	6,667	—	14	—	—	14
Issuance of common stock for employee 401(k) plan match	843,100	8	1,071	—	—	1,079
Foreign currency translation adjustments	—	—	—	—	(994)	(994)
Balance at April 30, 2023	49,669,488	\$ 496	\$ 342,055	\$ (325,780)	\$ 2,157	\$ 18,928

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)(in thousands)
(in thousands)

	Three Months Ended October 31,	
	2024	2023
Cash flows from operating activities:		
Net loss	\$ (3,376)	\$ (6,616)
Adjustments to reconcile net loss to net cash used in operating activities:		
Change in fair value of convertible debentures	—	328
Depreciation and amortization of property, plant and equipment	319	270
Share-based compensation charges	171	1,075
Share-based 401(k) employer match expense	109	109
Unrealized foreign exchange loss	165	970
Changes in operating assets and liabilities:		
Accounts receivable	(17)	2,019
Inventories	277	428
Prepaid expenses and other assets	469	346
Accounts payable – trade	(324)	(5,601)
Accrued liabilities, other current liabilities and other liabilities	(6,783)	(6,702)
Total adjustments	<u>(5,614)</u>	<u>(6,758)</u>
Net cash used in operating activities	<u>(8,990)</u>	<u>(13,374)</u>
Cash flows from investing activities:		
Release of escrowed cash from Asset Purchase Agreement	5,000	—
Capital expenditures	(448)	(254)
Net cash provided by (used in) investing activities	<u>4,552</u>	<u>(254)</u>
Cash flows from financing activities:		
Repayments under loan agreement and capital leases	(37)	(51)
Cash payments for taxes related to net share settlements of equity awards	(163)	(467)
Net cash used in financing activities	<u>(200)</u>	<u>(518)</u>
Effect of exchange rate changes on cash and cash equivalents	<u>2</u>	<u>(20)</u>
Decrease in cash and cash equivalents	(4,636)	(14,166)
Cash and cash equivalents - beginning of period	52,371	83,373
Cash and cash equivalents - end of period	<u>\$ 47,735</u>	<u>\$ 69,207</u>

	Nine Months Ended April 30,	
	2024	2023
Cash flows from operating activities:		
Net loss	\$ (12,697)	\$ (37,142)
Adjustments to reconcile net loss to net cash used in operating activities:		
Change in fair value of convertible debentures	1,095	—
Depreciation and amortization of property, plant and equipment	874	2,076
Share-based compensation charges	1,543	1,508
Share-based 401(k) employer match expense	494	772
Unrealized foreign exchange loss (gain)	764	(1,081)
Gain on operating lease terminations	(554)	—
Changes in operating assets and liabilities:		
Accounts receivable	2,475	1,861
Inventories	636	91
Prepaid expenses and other assets	(88)	1,350
Accounts payable – trade	(7,654)	5,128
Accrued liabilities, other current liabilities and other liabilities	(12,062)	5,492
Total adjustments	(12,477)	17,197
Net cash used in operating activities	(25,174)	(19,945)
Cash flows from investing activities:		
Capital expenditures	(422)	(2,187)
Net cash used in investing activities	(422)	(2,187)
Cash flows from financing activities:		
Proceeds from exercise of stock options	—	14
Proceeds from borrowings under Revolving Credit Agreement	—	7,565
Repayments under Revolving Credit Agreement	—	(4,211)
Repayments under mortgage agreement and capital leases	(110)	(253)
Cash payments for taxes related to net share settlements of equity compensation and awards	(474)	—
Net cash (used in) provided by financing activities	(584)	3,115
Effect of exchange rate changes on cash and cash equivalents	(37)	46
Decrease in cash and cash equivalents and restricted cash	(26,217)	(18,971)
Cash and cash equivalents and restricted cash - beginning of period	83,373	22,603
Cash and cash equivalents and restricted cash - end of period	\$ 57,156	\$ 3,632
Composition of cash and cash equivalents and restricted cash is as follows:		
Cash and cash equivalents	57,156	2,632
Restricted cash	—	1,000
Total cash and cash equivalents and restricted cash	\$ 57,156	\$ 3,632

The accompanying notes are an integral part of these consolidated financial statements.

ENZO BIOCHEM, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
As of April 30, 2024 October 31, 2024
(unaudited)
(Dollars in thousands except share data)

Note 1 – Basis of Presentation

Enzo Biochem, Inc. (the “Company,” “we,” “Company,” “we,” “our” or “Enzo”) has operated as a life sciences company for over 45 years. The primary business of Enzo today is conducted through its Enzo Life Sciences division (“Enzo Life Sciences”), is a manufacturer which focuses on labeling and supplier of detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. Enzo Biochem, Inc.’s Life Science division supports the work of research centers strives to enable a healthier world using scientific innovation through drug discovery, development and industry partners. Enzo Biochem, Inc. has a broad and deep intellectual property portfolio, with patent coverage across many vital enabling technologies, diagnostic solutions.

The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Inc. (“Enzo Life Sciences”), Enzo Therapeutics, Inc. (“Enzo Therapeutics”), Enzo Realty LLC (“Enzo Realty”), and Enzo Realty II LLC (“Enzo Realty II”), collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies.” The financial statements also include as discontinued operations the accounts of its wholly owned wholly-owned subsidiary Enzo Clinical Labs, Inc. (“Enzo Clinical Labs”). Effective July 24, 2023, we completed the sale of certain assets used in its our clinical services operations to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”), and thereby exited the clinical services business. See Note 2.

The Company has We have one reportable segment, Products. The consolidated balance sheet as of April 30, 2024 October 31, 2024, the consolidated statements of operations, comprehensive loss and stockholders’ equity for the three and nine months ended April 30, 2024 October 31, 2024 and 2023, and the consolidated statements of cash flows for the nine three months ended April 30, 2024 October 31, 2024 and 2023 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the fiscal year ended July 31, 2023 July 31, 2024 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2023 July 31, 2024 has been derived from the audited financial statements at that date. The results of operations for the nine three months ended April 30, 2024 October 31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2024 July 31, 2025.

Principles of consolidation

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) GAAP and include the accounts of the Company and its wholly-owned subsidiaries, Enzo Life Sciences (and its wholly-owned foreign subsidiaries), Enzo Therapeutics, Enzo Realty, Enzo Realty II, and Enzo Clinical Labs (a corporate entity with discontinued operations), subsidiaries. All intercompany transactions and balances have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Contingencies

Contingencies are evaluated and a liability is recorded when the matter is both probable and reasonably estimable. Gain contingencies are evaluated and not recognized until the gain is realizable or realized.

Foreign Currency Translation/Transactions

The Company has determined that the functional currency for its foreign subsidiaries is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting foreign currency translation adjustments are recognized as other comprehensive income (loss) in the consolidated statements of comprehensive loss and are included as a separate component of stockholders' equity as accumulated other comprehensive income. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations.

Fair Value Measurements

The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.

Level 1 Quoted prices in active markets for identical assets or liabilities.

Level 2 Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3 Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

Cash and cash equivalents

Cash and cash equivalents consist of demand deposits with banks and highly liquid money market funds. At April 30, 2024 October 31, 2024 and July 31, 2023 July 31, 2024, the Company had cash and cash equivalents in foreign bank accounts of \$1,240 \$186 and \$419, \$391, respectively.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. At April 30, 2024 October 31, 2024 and July 31, 2023 July 31, 2024, the Company had cash deposited in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents or restricted cash.

Concentration of credit risk with respect to the Company's Products segment is mitigated by the diversity of the Company's customers and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited.

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Effect of New Accounting Pronouncements - Recently

Pronouncements Issued but Not Yet Adopted Accounting Pronouncements

In June 2016, December 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-13 Accounting Standards Update (ASU) 2023-09, *Financial Instruments – Credit Losses* Income Taxes (Topic 326) 740): Improvements to Income Tax Disclosures. The amended guidance enhances income tax disclosures primarily related to the effective tax rate reconciliation and income taxes paid information. This standard changes guidance requires disclosure of specific categories in the impairment model for most financial instruments, including trade receivables, from an incurred loss method effective tax rate reconciliation and further information on reconciling items meeting a quantitative threshold. In addition, the amended guidance requires disaggregating income taxes paid (net of refunds received) by federal, state, and foreign taxes. It also requires disaggregating individual jurisdictions in which income taxes paid (net of refunds received) is equal to a new forward-looking approach, based on expected losses, or greater than five percent of total income taxes paid (net of refunds received). The estimate of expected credit losses amended guidance will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. We adopted this standard be effective for our interim period fiscal year beginning August 1, 2023 using a modified retrospective transition approach, August 1, 2025. The guidance can be applied either prospectively or retrospectively. We are currently in the process of evaluating the impact of this amended guidance may have on the adoption of this standard on footnotes to our results of operations, consolidated financial position and cash flows was not material statements.

In November 2023, FASB issued ASU No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* (ASU (ASU 2023-07), which requires an enhanced disclosure of significant segment expenses on an annual and interim basis. This guidance will be effective for our annual period ending July 31, 2025 July 31, 2026 and our interim periods beginning August 1, 2025. Early adoption is permitted. Upon adoption, we expect the guidance will be applied retrospectively to all prior periods presented in the consolidated financial statements. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the reported results of operations or discontinued operations.

Note 2 – Discontinued operations

Prior to July 24, 2023, we operated a clinical laboratory, doing business as Enzo Clinical Labs, which provided reference, molecular and esoteric diagnostic medical testing services in the New York, New Jersey, and Connecticut medical communities. Effective July 24, 2023, we completed the sale of certain assets used in the operation of Enzo Clinical Labs and the assignment of certain clinical lab liabilities to Labcorp Laboratory Corporation of America (“Labcorp”) for an aggregate purchase price of \$113.25 million in cash, subject to customary closing adjustments, cash. In connection accordance with the sale, \$5 million of escrowed proceeds were included in prepaid and other assets as of April 30, 2024 and in other assets as of July 31, 2023. we ceased our clinical services operations. Excluded from the sale of the clinical services assets were its cash and accounts receivable. In accordance with the sale, we ceased our clinical services operations but continue winding down activities. As a consequence of the sale, for the three and nine months ended April 30, 2024 and 2023 we have classified as discontinued operations all income and expenses attributable to the clinical services business. business for the fiscal year 2025 and 2024 periods presented.

The following table sets forth the condensed operating results of the discontinued operations for the three and nine months ended April 30: October 31,

	Three Months Ended April 30		Nine Months Ended April 30	
	2024	2023	2024	2023
Net revenues	\$ —	\$ 8,622	\$ —	\$ 28,619
Cost of revenues	—	9,993	—	30,538
Selling, general and administrative	835	5,810	3,085	18,207
Research and development	—	91	—	694
Legal and related expenses	—	21	—	192
Other (income) expense, net	444	(3)	1,333	(12)
Income tax (benefit)	(390)	—	(390)	—
Loss from discontinued operations	<u>\$ (889)</u>	<u>\$ (7,290)</u>	<u>\$ (4,028)</u>	<u>\$ (21,000)</u>

Other expense, net for the nine months ended April 30, 2024 is primarily the cost for a third party to maintain and destroy health records according to statute related to the discontinued operations.

	2024	2023
General and administrative	250	1,437
Other expense (income)	55	(496)
Loss from discontinued operations	<u>\$ (305)</u>	<u>\$ (941)</u>

The following table sets forth the condensed carrying amounts of major classes of assets and liabilities of the discontinued operations as of the dates indicated:

	April 30, 2024	July 31, 2023	October 31, 2024	July 31, 2024
<u>Carrying amounts of major current assets included as part of discontinued operations:</u>				
Trade receivables	\$ 97	\$ 1,675		
Prepaid and other current	313	54	\$ 53	\$ 182
Total current assets	<u>410</u>	<u>1,729</u>		
<u>Carrying amounts of major current liabilities included as part of discontinued operations:</u>				
Trade payables and accrued liabilities	8,709	20,616		
Accrued liabilities and trade payables			8,312	14,979
Operating lease liabilities and other	1,985	2,215	2,024	1,990
Total current liabilities	<u>10,694</u>	<u>22,831</u>	<u>10,336</u>	<u>16,969</u>
Current liabilities of discontinued operations, net	<u>10,284</u>	<u>21,102</u>	<u>\$ 10,283</u>	<u>\$ 16,787</u>
<u>Carrying amount of major non-current assets included as part of discontinued operations:</u>				
Right of use assets	\$ 5,658	\$ 7,001		
Right-of-use assets			\$ 1,195	\$ 1,308
Other	78	62	62	75
Total non-current assets	<u>5,736</u>	<u>7,063</u>	<u>1,257</u>	<u>1,383</u>
<u>Carrying amount of major non-current liabilities included as part of discontinued operations:</u>				
Operating lease liabilities and other	4,191	6,096	3,129	3,649
Non-current assets of discontinued operations, net	<u>\$ 1,545</u>	<u>\$ 967</u>		
Non-current liabilities of discontinued operations, net			<u>\$ 1,872</u>	<u>\$ 2,266</u>

During the **nine** three months ended **April 30, 2024** October 31, 2024, the cash used in operating and investing activities of the discontinued operations was **\$14,219** and **\$0**, respectively, **\$6,842**, primarily for reductions of trade payables and accrued liabilities,

partially offset by collections of accounts receivable, and the period loss. liabilities. During the nine three months ended April 30, 2023 October 31, 2023, the cash used in operating activities and investing activities of the discontinued operations was \$12,564 \$8,082, primarily for reductions of trade payables and \$447, respectively, accrued liabilities.

Note 3 – Net income (loss) loss per share

Basic net income (loss) loss per share represents net income (loss) loss divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares, consisting of outstanding stock options, and unvested restricted stock units and performance stock units, is determined using the treasury stock method. As a result of the net loss for the three and nine months ended April 30, 2024 October 31, 2024 and 2023, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options, restricted stock units, warrants, assumed conversion of debentures, or unearned performance stock units warrants because to do so would be anti-dilutive.

For the three and nine months ended April 30, 2024 October 31, 2024, the effect of approximately 1,832,000 and 2,542,000, respectively, 2,125,000 of outstanding “out of the money” options to purchase common shares and the effect of approximately 77,000 35,000 of outstanding restricted stock units were excluded from the calculation of diluted net (loss) per share because their effect would be anti-dilutive. Also, for the three months ended October 31, 2024, the effect of approximately 1,062,000 warrants related to debentures repaid in May 2024 were excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive. The warrants related to the debentures are eligible for any dividends paid on the common stock and 133,000, respectively, are therefore considered to be participating securities which do not have any contractual obligation to share in the Company’s losses. The impact on net loss per share under the two-class method was not material.

For the three months ended October 31, 2023, the effect of approximately 3,320,000 of outstanding “out of the money” options to purchase common shares and the effect of approximately 54,000 of outstanding restricted stock units were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive. During Also for the three and nine months ended April 30, 2024 October 31, 2023, the effect of approximately 848,000 and 688,000, respectively, of shares related to 593,000 warrants and the effect of approximately 1,688,000 and 1,438,000, respectively of 1,199,000 shares related to the assumed conversion of debentures repaid in May 2024 were excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive.

For the three and nine months ended April 30, 2023, approximately 173,000 and 105,000, respectively, of potential common shares from “in the money options” and unvested restricted stock and performance stock units were excluded from the calculation of diluted (loss) per share because their effect would be antidilutive. For the three and nine months ended April 30, 2023, the effect of approximately 4,097,000 and 3,627,000, respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net (loss) income per share because their effect would be anti-dilutive.

Note 4 – Revenue Recognition

Products Revenue

The Company generates revenue from the sale of our single-use products used in the identification of genomic information. Revenue is recorded net of sales tax. The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products are identified; the transaction price is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of revenues.

Products revenue by geography is as follows:

	Three Months Ended April 30		Nine Months Ended April 30		Three Months Ended October 31	
	2024	2023	2024	2023	2024	2023
United States	\$ 4,793	\$ 5,043	\$ 14,594	\$ 13,282	\$ 3,764	\$ 4,635
Europe	2,359	1,688	6,783	5,869	1,664	2,138
Asia Pacific	870	754	3,004	2,951	785	1,033
Products revenue	<u>\$ 8,022</u>	<u>\$ 7,485</u>	<u>\$ 24,381</u>	<u>\$ 22,102</u>	<u>\$ 6,213</u>	<u>\$ 7,806</u>

As of August 1, 2023 August 1, 2024 and 2022, 2023, accounts receivable from continuing operations was \$3,988 and \$4,808, and \$4,762, respectively.

Note 5 – Supplemental disclosure for statement of cash flows

During the ~~nine~~three months ended ~~April 30, 2024~~~~October 31, 2024~~ and 2023, interest paid by the Company was ~~\$275~~\$2 and ~~\$204~~, \$92, respectively.

For the ~~nine~~three months ended ~~April 30, 2024~~~~October 31, 2024~~ and 2023, the net reductions in the measurement of ~~right of use~~right-of-use assets and liabilities included in cash flows from operating activities was ~~\$306~~\$389 and ~~\$5~~, \$148, respectively. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statement of cash flows.

In connection with the completed sale of certain assets used in the operation of Enzo Clinical Labs ~~at the end of fiscal 2023~~, \$5,000 of escrowed proceeds ~~were~~are included in ~~prepaid and other assets~~cash in escrow as of ~~April 30, 2024~~ and in other assets as ~~July 31, 2024~~. As of ~~July 31, 2023~~. In connection with ~~October 31, 2024~~, these escrowed proceeds were released to the ~~full payment of a mortgage in July 2023~~, Company.

During the ~~restricted cash collateral deposit of \$1,000 was released during the~~ ~~nine~~three months ended ~~April 30, 2024~~.

During the nine months ended April 30, 2024, state taxes paid on the gain on the completed sale of certain assets used in the operation of Enzo Clinical Labs were \$729. For the nine months ended April 30, 2024 and 2023, tax on capital paid by the Company was \$23 and \$9, respectively.

During the nine months ended April 30, 2024 October 31, 2024, the Company disbursed \$474 \$163 for taxes related to net share settlement of a bonus paid in stock to a senior executive. During the three months ended October 31, 2023, the Company disbursed \$467 for taxes related to net share settlement of bonuses paid in stock to a current senior executive and a former senior executive, executive.

On October 29, 2024, the Board of Directors of the Company declared a cash dividend of \$0.10 per share on its common stock, which was paid on December 2, 2024, to the holders of record as of the close of business on November 15, 2024. The total dividend payable was \$5,324 and for taxes related to is a net share settlement component of a performance stock unit, the total current liabilities balance as of October 31, 2024.

Note 6 – Inventories

Inventories, net consisted of the following as at:of the dates indicated:

	April 30, 2024	July 31, 2023
Raw materials	\$ 2,067	\$ 2,206
Work in process	2,708	2,599
Finished products	2,549	3,134
	<u>\$ 7,324</u>	<u>\$ 7,939</u>
	October 31, 2024	July 31, 2024
Raw materials	\$ 1,482	\$ 1,794
Work in process	2,386	2,461
Finished products	2,523	2,577
	<u>\$ 6,391</u>	<u>\$ 6,832</u>

Note 7 – Convertible debentures and other current debt

On May 19, 2023, In May 2023, the Company entered into consummated a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers that are parties thereto (each, including its successors and assigns, a “Purchaser” and collectively, Purchasers, as defined in the “Purchasers”) Purchase Agreement, and JGB Collateral, LLC, a Delaware limited liability company, as collateral agent for the Purchasers (the “Agent”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 10% Original Issue Discount Secured Convertible Debentures (the “Debentures”) with an aggregate principal amount of \$7,608 and (ii) warrants to purchase up to 1,000,000 shares of the Company’s common stock, par value \$0.01 per share (the “Common Stock”), for an exercise price of \$2.31 per share, the average of the three (3) daily volume weighted average prices of the Common Stock as defined in the Purchase Agreement (“VWAP”) prior to the closing date (the “Warrants”), subject to adjustments as set forth in the Warrants, for a total purchase price of \$7,000. The Purchase Agreement contains customary representations, warranties and covenants. The transactions contemplated by the Purchase Agreement were consummated on May 19, 2023. Pursuant to ASC 825, Fair Value Option, the Company made an irrevocable election at the time of issuance to report the Debentures at fair value with changes in fair value recorded through the Company’s consolidated statements of operations as other income (expense) in each reporting period. During the three months ended October 31, 2023, the change in fair value expense recorded was \$328.

Debentures

The Debentures bear **bore** interest at a rate of 10% per annum (which interest rate is increased to 18% per annum five days after the occurrence and continuance of an Event of Default (as defined in the Debentures)), have a maturity date of May 20, 2024 and are **annum**. The Debentures were convertible, at any time after their issuance date at the option of the Purchasers, into shares of Common Stock at a conversion price equal to \$3.01 per share (the “Conversion Price”), subject to adjustment as set forth in the Debentures. Following the July 24, 2023 consummation of the Company’s sale of certain assets and assignment of certain liabilities of Enzo Clinical Labs, **Inc.**, to Labcorp pursuant to the Asset Purchase Agreement dated March 16, 2023, the Company prepaid \$4,000 of the outstanding principal amount prior to July 31, 2023.

The Company’s obligations under the Debentures may be accelerated, at the Purchasers’ election, upon the occurrence of certain customary events of default. As of April 30, 2024 and July 31, 2023, there were no events of default. The Debentures contain customary representations, warranties and covenants including among other things and subject to certain exceptions, covenants that restrict **In May 2024**, the Company from incurring additional indebtedness, creating or permitting liens on assets, amending its charter documents and bylaws, repurchasing or otherwise acquiring more than a de minimis number of its Common Stock or equivalents thereof, repaying outstanding indebtedness, paying dividends or distributions, assigning or selling certain assets, making or holding any investments, and entering into transactions with affiliates.

The following table presents a reconciliation of the beginning and ending balances of the Debentures measured at fair value on a recurring basis that use significant unobservable inputs (Level 3) and the related change in fair value expense recorded in the consolidated statement of operations during the nine months ended April 30, 2024:

Fair value, July 31, 2023	\$ 2,514
Change in fair value of convertible debentures	1,095
Fair value, April 30, 2024	<u>\$ 3,609</u>

During the three months ended April 30, 2024, the change in fair value expense recorded was \$384.

As of April 30, 2024, the outstanding principal of the Debentures was \$3,609, which was paid repaid in full plus interest the remaining principal balance of \$20, on May 20, 2024, the date the Debentures matured.

Security Agreement and Subsidiary Guarantees

In connection with the Purchase Agreement, on May 19, 2023, the Company, certain of the Company's domestic subsidiaries ("Guarantors"), the Purchasers and the Agent entered into a Security Agreement (the "Security Agreement"), pursuant to which the Company and the Guarantors granted, for the benefit of the Purchasers, to secure the Company's obligations under the Purchase Agreement and the Debentures. Subsequent to the payoff of the Debentures on May 20, 2024, all obligations under the Security Agreement were terminated. \$3,609.

Warrants

The Warrants are exercisable for five years from May 19, 2023, at an exercise price of \$2.31 per share, which is the average of three (3) daily VWAPs prior to the closing date, subject, with certain exceptions, to adjustments in the event of stock splits, dividends, subsequent dilutive offerings and certain fundamental transactions, as more fully described in the Warrant. The Warrants are eligible for any dividends paid on common stock.

Registration Rights Agreement

In connection with the Purchase Agreement, on May 19, 2023, the Company and the Purchasers entered into was obligated to file a Registration Rights Agreement, registration statement pursuant to which the Company is obligated to register Purchasers could sell the shares of Company Common Stock issuable upon exercise the conversion of the Debentures and the Warrants. The Company has registered the shares. With the full payoff exercise of the Debentures, there warrants in a public offering. There is no longer a right to a conversion of the Debentures into shares. shares as the Debentures have been repaid in full.

Note 8 – Long term debt

In April 2020, the Company's subsidiary in Switzerland received a loan of CHF 400 (or \$400, based on the foreign exchange rate as of July 31, 2020) from the Swiss government under the "Corona Krise" emergency loan program in response to the COVID-19 pandemic. This loan is uncollateralized and bears 0% interest. In January 2022, the bank agent of the Swiss government informed our subsidiary that the loan had to be fully amortized within a maximum of eight years and that the first of semiannual amortization payments of CHF 33 would begin began in March 2022. In March 2022, the subsidiary made its first semi-annual principal repayment of CHF 33 (or \$35 based on exchange rates). Based on this amortization schedule, the loan will be repaid by September 2027. The current portion of this loan is included in other current liabilities and the long term portion in long term debt – net as of April 30, 2024 October 31, 2024 and July 31, 2023 July 31, 2024.

Minimum future annual principal payments under this agreement as of **April 30, 2024** **October 31, 2024** are as follows:

July 31,	Total	Total
2024	\$ —	
2025	73	\$ 39
2026	73	77
2027	73	77
2028	36	38
Total principal payments	255	231
Less: current portion	(75)	
Less: current portion, included in other current liabilities		(76)
Long term debt – net	\$ 180	\$ 155

Note 9 – Leases

The Company determines if an arrangement is or contains a lease at contract inception. The Company leases buildings, office space, and equipment through operating leases. Generally, a right-of-use asset, representing the right to use the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company primarily uses its incremental borrowing rate in determining the present value of lease payments as the Company's leases generally do not provide an implicit rate.

The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (e.g., payments related to maintenance fees, utilities, etc.) which have generally been combined and accounted for as a single lease component. The Company's leases have remaining terms of less than 1 year to 4 years, some of which include options to extend the leases for up to 3 years. **The Certain of the Company's lease leases have terms may that include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised.**

Certain of the Company's lease agreements include rental payments adjusted periodically for inflation **or a market rate** which are included in the lease liabilities.

Leases	Balance Sheet Classification	April 30, 2024	July 31, 2023
Assets			
Operating	Right-of-use assets	\$ 2,959	\$ 3,626
Total lease assets		\$ 2,959	\$ 3,626
Liabilities			
Current:			
Operating	Current portion of operating lease liabilities	\$ 799	\$ 980
Non-current:			
Operating	Operating lease liabilities, non-current	2,595	3,160
Total lease liabilities		\$ 3,394	\$ 4,140

Components The following table summarizes the Company's right of use assets and associated liabilities as of the dates indicated:

Leases	Balance Sheet Classification	October 31, 2024	July 31, 2024
Assets			
Operating	Right-of-use assets	\$ 2,654	\$ 2,836
Total lease assets		<u>\$ 2,654</u>	<u>\$ 2,836</u>
Liabilities			
Current:			
Operating	Current portion of operating lease liabilities	\$ 827	\$ 841
Non-current:			
Operating	Operating lease liabilities, non-current	2,209	2,403
Total lease liabilities		<u>\$ 3,036</u>	<u>\$ 3,244</u>

For the three months ended October 31, components of lease cost were as follows:

	Three months ended April 30,		Nine months ended April 30,	
	2024	2023	2024	2023
Operating lease cost – net (a)	\$ 141	\$ 108	\$ 422	\$ 472

Lease Cost	2024	2023
Operating lease cost – net (a)	\$ 95	\$ 141

(a) Net of \$126 and \$378 of sublease income for the three and nine months ended April 30, 2024, respectively, October 31, 2024 and \$126 and \$252 for the three and nine months ended April 30, 2023, respectively. 2023.

The maturities of the Company's lease liabilities as of April 30, 2024 October 31, 2024 are as follows:

Maturity of lease liabilities, years ending July 31,	Operating leases	Operating leases
2024	\$ 278	
2025	896	\$ 731
2026	886	886
2027	881	881
2028	808	808
Total lease payments	3,749	3,306
Less: Interest (a)	(355)	(270)
Present value of lease liabilities	<u>\$ 3,394</u>	<u>\$ 3,036</u>

(a) Primarily calculated using the Company's incremental borrowing rate.

Lease term and discount rate for the **nine**three months ended **April 30****October 31** were as follows:

Lease term and discount rate	2024	2023
Weighted-average remaining lease term (years) - operating leases	4.1 years	5.1 years
Weighted-average discount rate – operating leases	5.1 %	5.1 %

Lease term and discount rate	2024	2023
Weighted-average remaining lease term (years):		
Operating leases	3.6 years	4.5 years
Weighted-average discount rate:		
Operating leases	5.2 %	5.1 %

See Note 5 for cash flow information on cash paid for amounts included in the measurement of lease liabilities for the **nine**three months ended **April 30, 2024****October 31, 2024** and 2023.

Note 10 – Accrued **Liabilities** liabilities and **other** current liabilities

Accrued liabilities as of the date indicated consist of:

	April 30, 2024	July 31, 2023	October 31, 2024	July 31, 2024
Payroll, benefits and commissions	\$ 3,053	\$ 7,421	\$ 3,197	\$ 3,459
Professional fees	451	610	434	405
Legal	1,282	2,248	1,472	1,235
Other	590	1,464	515	615
	<u>\$ 5,376</u>	<u>\$ 11,743</u>	<u>\$ 5,618</u>	<u>\$ 5,714</u>

Self-Insured Medical Plan

The Company self-funds medical insurance coverage for certain of its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stop loss insurance. As of **April 30, 2024** **October 31, 2024** and **July 31, 2023** **July 31, 2024**, the Company had established reserves of **\$99** **\$158** and **\$631** **\$114**, respectively, which are included in accrued liabilities for payroll, benefits and commissions, for claims that have been reported but not paid and for claims that have been incurred but not reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates.

Dividend payable

On October 29, 2024, the Board of Directors of the Company declared a cash dividend of \$0.10 per share on its common stock, which was paid on December 2, 2024, to the holders of record as of the close of business on November 15, 2024. The dividend paid amounted to \$5,324.

Controlled Equity Offering

In May 2023, the Company entered into a sales agreement (the "Sales Agreement") with B. Riley Securities, Inc. as sales agent ("Riley"). Under the Sales Agreement, the Company may offer and sell, from time to time, through Riley, shares of the Company's common stock, par value \$0.01 per share ("Shares") having an aggregate offering price of up to \$30 million. The Company pays Riley a commission of 3.0% of the aggregate gross proceeds received under the Sales Agreement. The Company is not obligated to make any sales of Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Riley or the Company, as permitted therein. In May 2023, the Company filed with the SEC a "shelf" registration and sales agreement prospectus covering the Sales Agreement. A total of \$150 million of securities, including those covered by the Sales Agreement, may be sold under the shelf registration which was declared effective in July 2023. During the fourth quarter of the fiscal year ended July 31, 2023, the Company sold 276,479 shares for net proceeds of \$386. There was no activity with respect to the controlled equity offering during the nine three months ended April 30, 2024, October 31, 2024 or 2023.

Incentive stock plans

In January 2011, the Company's stockholders approved the adoption of the 2011 Incentive Plan (the "2011 Plan") for the issuance of equity awards, including, among others, options, restricted stock, restricted stock units and performance stock units for up to 3,000,000 shares of common stock. In January 2018, the Company's stockholders approved the amendment and restatement of the 2011 Plan (the "Amended and Restated 2011 Plan") to increase the number of shares of common stock available for grant under the 2011 Plan by 2,000,000 shares of common stock bringing the total number of shares available for grant to 5,000,000 shares of common stock. On October 7, 2020, the Company's Board of Directors approved the amendment and restatement of the Amended and Restated 2011 Plan, with an effective date of October 7, 2020 and subject to approval by the Company's stockholders at the 2020 annual meeting of stockholders of the Company. The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030. In At the fiscal 2020 annual stockholders' meeting in January 2021, the Company's stockholders approved the amendment and restatement of the Amended and Restated 2011 Plan.

The exercise price of options granted under the Amended and Restated 2011 Plan as amended and restated, is equal to or greater than fair market value of the common stock on the date of grant. The Amended and Restated 2011 Plan as amended and restated, will terminate at the earliest of (a) such time as no shares of common stock remain available for issuance under the plan, (b) termination of the plan by the Company’s Board of Directors, or (c) October 7, 2030. Awards outstanding upon expiration of the Amended and Restated 2011 Plan as amended and restated, will remain in effect until they have been exercised or terminated, or have expired. As of April 30, 2024October 31, 2024, there were approximately 5,006,0004,698,000 shares of common stock available for grant under the Amended and Restated 2011 Plan, as amended and restated. Plan.

The Company estimates the fair value of each stock option award on the measurement date using a Black-Scholes option pricing model or the fair value of our stock at the date of grant. The fair value of awards is amortized to expense on a straight-line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, primarily time elapsed. Performance stock awards
The amounts of share-based compensation expense recognized in the periods presented are not recognized until it is probable they will be earned. At such time, their as follows:

	Three months ended October 31,	
	2024	2023
Stock options	\$ 104	646
Restricted stock units	67	429
	<u>\$ 171</u>	<u>1,075</u>

The following table sets forth the amount of expense is then recognized over related to share-based payment arrangements included in specific line items in the requisite service period, including that portion accompanying statements of the service period already elapsed. Options granted pursuant to the plans may be either incentive stock options or non-statutory options. The 2011 Plan provides for the issuance of stock options, restricted stock and restricted stock unit awards which generally vest over a two or three year period. operations:

	Three months ended October 31,	
	2024	2023
Selling, general and administrative	\$ 163	1,069
Cost of revenues	8	6
	<u>\$ 171</u>	<u>1,075</u>

During the nine three months ended April 30, 2024October 31, 2023, the Company recognized in selling, general and administrative expense \$519 of share based compensation with respect to stock options and \$367 of share based compensation with respect to restricted stock units as a result of the termination of the former CEO during the period then ended. See Note 14. CEO.

The amounts of share-based compensation expense recognized in the periods presented are as follows:

	Three months ended		Nine months ended	
	April 30,		April 30,	
	2024	2023	2024	2023
Stock options and performance stock units	\$ 90	\$ 211	\$ 833	\$ 622
Restricted stock units	117	277	710	666
	<u>\$ 207</u>	<u>\$ 488</u>	<u>\$ 1,543</u>	<u>\$ 1,288</u>

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

	Three months ended		Nine months ended	
	April 30,		April 30,	
	2024	2023	2024	2023
Selling, general and administrative	\$ 199	\$ 482	\$ 1,518	\$ 1,271
Cost of revenues	8	6	25	17
	<u>\$ 207</u>	<u>\$ 488</u>	<u>\$ 1,543</u>	<u>\$ 1,288</u>

No excess tax benefits were recognized during the nine three month periods ended April 30, 2024 October 31, 2024 and 2023.

The following table summarizes stock option activity during the **nine** **three** month period ended **April 30, 2024** **October 31, 2024**:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at July 31, 2023	3,829,500	\$ 2.61		—				
Outstanding at July 31, 2024					2,136,870	\$ 2.31		—
Granted	125,000	1.38			5,000	1.11		
Exercised	—	—		\$	—	—		
Cancelled or expired	(2,122,630)	\$ 1.61			(1,500)	\$ 3.32		
Outstanding at end of period	<u>1,831,870</u>	<u>\$ 2.37</u>	<u>2.1 years</u>	<u>\$ —</u>	<u>2,140,370</u>	<u>\$ 2.31</u>	<u>1.4 years</u>	<u>—</u>
Exercisable at end of period	<u>1,215,203</u>	<u>\$ 2.49</u>	<u>1.8 years</u>	<u>\$ —</u>	<u>1,372,037</u>	<u>\$ 2.44</u>	<u>1.4 years</u>	<u>—</u>

As of **April 30, 2024** **October 31, 2024**, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was **\$491** **\$359** and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately one and one half years. The intrinsic value of stock option awards **represents is** the value of the Company's closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options that are outstanding.

Restricted Stock Units

The following table summarizes RSU activity for the **nine** **three** months ended **April 30, 2024** **October 31, 2024**:

	Number of RSUs outstanding	Weighted Average Fair Value per Unit at Date of Grant	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at beginning of fiscal year	557,490	\$ 2.21	1.1 years	825
Granted	405,825	\$ 1.31		—
Vested	(475,222)	\$ 2.24		
Cancelled	(100,000)	\$ 1.97		
Outstanding at end of period	388,093	\$ 1.31	1.5 years	\$ 404
Expected to vest at end of period	388,093	\$ 1.31	1.5 years	\$ 404

Certain directors had not received their vested RSU shares, totaling 144,530, as of July 31, 2023. These shares were issued during the nine months ended April 30, 2024.

During the nine months ended April 30, 2024, 173,333 RSUs vested and 100,000 were cancelled as a result of the termination of the former CEO. The vested shares had not been issued as of April 30, 2024, but were subsequently issued in May 2024.

	Number of RSUs outstanding	Weighted Average Fair Value per Unit at Date of Grant	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value (000s)
Outstanding at beginning of fiscal year	308,730	\$ 1.31	1.5 years	352
Granted	—	\$ —		—
Vested	—	\$ —		
Cancelled	—	\$ —		
Outstanding at end of period	308,730	\$ 1.31	1.25 years	\$ 355
Expected to vest at end of period	308,730	\$ 1.31	1.25 years	\$ 355

During the three **and nine** months ended **April 30, 2024**, **October 31, 2024** and **2023**, the Company recognized shared based compensation expense for RSU's RSUs of **\$117** **\$67** and **\$710**, **\$429**, respectively. As of **April 30, 2024** **October 31, 2024**, the total future compensation cost related to non-vested RSUs, not yet recognized in the statements of operations, was **\$390** **\$189** and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately **one and a half** years.

Performance Stock Units

During the three and nine months ended April 30, 2024, the Company recognized no share based compensation for Performance Stock Units ("PSUs") because no PSUs were outstanding during either period. During the three and nine months ended April 30, 2023, the Company recognized \$7 and \$(41) of share based compensation (reversal of compensation) for PSUs. During the nine months ended April 30, 2024, the Company issued 4,817 shares of stock, net of taxes to a senior executive who had previously vested in the shares. **15 months.**

Note 12 – Segment reporting

The Company has one reportable segment, Products, which develops, manufactures, focuses on labeling and markets detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, to including antibodies, genomic probes, assays, biochemicals, and proteins. The Company's proprietary products and technologies play central roles in translational research and pharmaceutical customers, drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as "Corporate & Other" consist of corporate general and administrative costs, which are not allocable to the Products segment.

Legal and related expenses incurred to defend the Company's intellectual property, which may result in settlements recognized in another segment, and other general corporate matters are considered a component of the Corporate & Other segment. Legal and related expenses specific to the Products' segment's activities are allocated to that segment.

Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies.

The following financial information represents the operating results of the reportable segments of the Company: Company for the period indicated:

Three months ended April 30, 2024 October 31, 2024

	Products	Corporate & Other	Consolidated	Products	Corporate & Other	Consolidated
Revenues	\$ 8,022	\$ —	\$ 8,022	\$ 6,213	\$ —	\$ 6,213
Operating costs and expenses:						
Cost of revenues	4,289	—	4,289	3,681	—	3,681
Cost of revenues – inventory provision				252	—	252
Research and development	595	10	605	562	—	562
Selling, general and administrative	2,881	1,598	4,479	3,167	1,715	4,882
Legal and related expenses	—	692	692	6	452	458
Total operating costs and expenses	7,765	2,300	10,065	7,668	2,167	9,835
Operating income (loss)	257	(2,300)	(2,043)			
Operating loss				(1,455)	(2,167)	(3,622)
Other income (expense)						
Interest	37	689	726	—	620	620
Change in fair value of convertible debentures	—	(384)	(384)			
Other	(31)	125	94	—	123	123
Foreign exchange loss	(524)	—	(524)	(192)	—	(192)
Loss before taxes	\$ (261)	\$ (1,870)	\$ (2,131)	\$ (1,647)	\$ (1,424)	\$ (3,071)
Depreciation and amortization included above	\$ 162	\$ 175	\$ 337	\$ 229	\$ 87	\$ 316
Share-based compensation included above:						
Selling, general and administrative	32	167	199	32	131	163
Cost of sales	8	—	8	8	—	8
Total	\$ 40	\$ 167	\$ 207	\$ 40	\$ 131	\$ 171
Capital expenditures	\$ 123	\$ 20	\$ 143	\$ 448	\$ —	\$ 448
Three months ended April 30, 2023						
				Products	Corporate & Other	Consolidated
Revenues				\$ 7,485	\$ —	\$ 7,485

Operating costs and expenses:			
Cost of revenues	4,476	—	4,476
Research and development	872	12	884
Selling, general and administrative	3,069	3,143	6,212
Legal and related expenses	19	4,246	4,265
Total operating costs and expenses	<u>8,436</u>	<u>7,401</u>	<u>15,837</u>
Operating loss	(951)	(7,401)	(8,352)
Other income (expense)			
Interest	30	(66)	(36)
Other	2	142	144
Foreign exchange gain	347	—	347
Loss before taxes	<u>\$ (572)</u>	<u>\$ (7,325)</u>	<u>\$ (7,897)</u>
Depreciation and amortization included above	<u>\$ 182</u>	<u>\$ 93</u>	<u>\$ 275</u>
Share-based compensation included above:			
Selling, general and administrative	20	462	482
Cost of sales	6	—	6
Total	<u>\$ 26</u>	<u>\$ 462</u>	<u>\$ 488</u>
Capital expenditures	<u>\$ 331</u>	<u>\$ 282</u>	<u>\$ 613</u>

Nine Three months ended April 30, 2024 October 31, 2023

	Products	Corporate & Other	Consolidated
Revenues	\$ 24,381	\$ —	\$ 24,381
Operating costs and expenses:			
Cost of revenues	12,969	—	12,969
Research and development	2,012	23	2,035
Selling, general and administrative	9,266	7,284	16,550
Legal and related expenses	51	2,476	2,527
Total operating costs and expenses	24,298	9,783	34,081
Operating income (loss)	83	(9,783)	(9,700)
Other income (expense)			
Interest	104	2,491	2,595
Change in fair value of convertible debentures	—	(1,095)	(1,095)
Other	(28)	401	373
Foreign exchange loss	(842)	—	(842)
Loss before taxes	\$ (683)	\$ (7,986)	\$ (8,669)
Depreciation and amortization included above	\$ 500	\$ 374	\$ 874
Share-based compensation included above:			
Selling, general and administrative	97	1,421	1,518
Cost of sales	25	—	25
Total	\$ 122	\$ 1,421	\$ 1,543
Capital expenditures	\$ 369	\$ 53	\$ 422

Nine months ended April 30, 2023

	Products	Corporate & Other	Consolidated	Products	Corporate & Other	Consolidated
Revenues	\$ 22,102	\$ —	\$ 22,102	\$ 7,806	—	\$ 7,806
Operating costs and expenses:						
Cost of revenues	13,681	—	13,681	4,351	—	4,351
Research and development	2,675	33	2,708	838	\$ 11	849
Selling, general and administrative	8,989	8,089	17,078	3,104	3,903	7,007
Legal and related expenses	55	6,105	6,160	30	1,045	1,075
Total operating costs and expenses	25,400	14,227	39,627	8,323	4,959	13,282
Operating loss	(3,298)	(14,227)	(17,525)	(517)	(4,959)	(5,476)
Other income (expense)						
Interest	84	15	99	34	943	977
Change in fair value of convertible debentures				—	(328)	(328)
Other	6	256	262	2	156	158
Foreign exchange gain	1,022	—	1,022			
Income (loss) before taxes	\$ (2,186)	\$ (13,956)	\$ (16,142)			
Foreign exchange loss				(1,006)	—	(1,006)
Loss before taxes				\$ (1,487)	\$ (4,188)	\$ (5,675)
Depreciation and amortization included above	\$ 518	\$ 267	\$ 785	\$ 166	\$ 104	\$ 270
Share-based compensation included above:						
Selling, general and administrative	60	1,211	1,271	22	1,047	1,069
Cost of sales	17	—	17	6	—	6
Total	\$ 77	\$ 1,211	\$ 1,288	\$ 28	\$ 1,047	\$ 1,075
Capital expenditures	\$ 1,268	\$ 506	\$ 1,774	\$ 248	\$ 6	\$ 254

Note 13 – Contingencies

Ransomware Attack

In April 2023, the Company experienced a ransomware attack (the “ransomware attack”) that impacted certain critical information technology systems. In response, we promptly deployed containment measures, including disconnecting our systems, from the

internet, launching an investigation with assistance from third-party cybersecurity experts, and notifying law enforcement. We adhered to our disaster recovery plan, which enabled us to maintain operations throughout the incident response process. We are in the process of evaluating the full scope principally of the costs and related impacts of this incident. discontinued operations. The Company's facilities remained open, and we continued to provide services to patients and partners. We Company later became aware that certain data, including names, test information, and Social Security numbers, was accessed, and in some instances, exfiltrated from the Company's information technology systems as part of this incident. The investigation identified unauthorized access to or acquisition of clinical test information of approximately 2,470,000 individuals. The Social Security numbers of approximately 600,000 of these individuals may also have been involved. Additionally, the Company has determined that some employees' information may have been involved. The Company has provided notice to the individuals whose information may have been involved, as well as to regulatory authorities, in accordance with applicable law.

As a result of the ransomware attack, Enzo Biochem is currently was subject to regulatory inquiry from the New York Attorney General, a joint inquiry from the Connecticut and New Jersey Attorneys General and an inquiry from the Utah Attorney General. All inquiries ask asked questions about the ransomware attack, as well as the corrective actions taken in response. We The Company responded to all such inquiries, and there have been no further inquiries from the Utah Attorney General. The matters with the New York, Connecticut and New Jersey Attorneys General are unable to evaluate now closed, as they were resolved by agreements with each of the likelihood three states effective August 8, 2024. A provision was recorded in the consolidated financial statements as of an outcome, favorable or unfavorable, to July 31, 2024 based on the Company or to estimate settlement terms of the amount or range of any potential liability, if any, at this time. agreements.

Enzo Biochem is also subject to regulatory inquiries from the U.S. Department of Health and Human Services Office for Civil Rights (the “Office for Civil Rights”) regarding the ransomware attack. The Company has responded to all requests. It is not known at this time whether the Office for Civil Rights will seek a penalty against the Company. We are unable to evaluate the likelihood of an outcome, favorable or unfavorable, to the Company or to estimate the amount or range of any potential liability, if any, at this time.

There is also pending Class Action class action litigation:

In re Enzo Biochem Data Breach Litigation, No. 2:23-cv-04282 (EDNY)

In the Eastern District of New York (“EDNY”), twenty putative class actions have been were consolidated alleging various harms stemming from the April 2023 data incident. Interim lead Lead counsel has been was appointed and filed a Consolidated Amended Complaint on November 13, 2023. The complaint seeks sought to certify a federal class as well as several state subclasses. The Consolidated Amended Complaint brings various statutory and common law claims, including negligence, negligence per se, breach of fiduciary duty, breach of implied contract, breach of the implied covenant of good faith and fair dealing, violation of the New York’s General Business Law § 349, Invasion of Privacy, violations of the Connecticut Unfair Trade Practices Act, and violations of the New Jersey Consumer Fraud Act. An agreement in principle to settle the case has been reached. The Company filed its motion expects to dismiss on April 8, 2024. Plaintiffs filed their Opposition on May 23, 2024 and our Reply was filed on May 30, 2024. We are now awaiting have the court’s decision, agreement formalized before the end of the 2024 calendar year.

Maria Sgambati et al., v. Enzo Biochem, Inc., et al., Index No. 619511/2023 (N.Y. Sup. Ct.)

This is a putative class action pending in state court alleging various harms stemming from the April 2023 data incident. The complaint seeks to certify a class of New York residents. The complaint brings claims of negligence; negligence *per se*; breach of implied covenant and good faith and fair dealing; breach of duty; breach of implied contract; and violations of New York’s Deceptive Acts and Practices § 349. This court granted our The Company has filed a motion to stay this action pending the resolution of the EDNY Federal Action, and the motion was granted by the court. The Company anticipates that the case pending will be dismissed once the outcome of settlement in the federal action case receives final approval from the court, likely sometime in the Eastern District of New York, 2025.

Louis v. Enzo Biochem, Inc. et al., Index No. 653281/2023 (N.Y. Sup. Ct.)

This is a putative class action pending in state court alleging various harms stemming from the April 2023 data incident. The complaint seeks to certify a class of New York citizens. The complaint brings claims of negligence; negligence *per se*; breach of duty, duty; breach of implied contract; breach of implied covenant of good faith and fair dealing; and violations of New York’s Deceptive Acts and Practices § 349. We have The Company has filed a motion to stay this action pending the resolution of the federal action in the Eastern District of New York EDNY Federal Action, and the motion remains pending. The Company anticipates that the case will be dismissed once the settlement in the federal case receives final approval from the court, likely sometime in 2025.

A provision was made in the consolidated financial statements as of July 31, 2023 for the above class action litigation matters based on a reasonable estimate of loss; loss and updated as applicable as of October 31, 2024 and July 31, 2024; however, the actual exposure may differ.

Patent Matters

The Company (as plaintiff) has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. At this time, the majority all of such cases have been resolved, resolved, except for one described below.

There is currently one case that was originally brought by the Company that is still pending in the Court. In that case, Enzo alleges patent infringement of the '197 '197 patent against Becton Dickinson defendants. The claims in that case are stayed.

On September 2, 2021, the U.S. Patent and Trademark Office ("PTO") issued a non-final office action in an *ex parte* reexamination concerning the '197 '197 Patent. In the office action, the PTO rejected certain claims of the '197 '197 Patent under 35 U.S.C. §§ 102 and 103, and for nonstatutory double-patenting. Enzo responded to the office action on January 3, 2022, and the proceeding remains pending. Becton Dickinson requested another *ex parte* reexamination concerning the '197 '197 patent on July 26, 2022. On September 16, 2022, the PTO ordered that *ex parte* reexamination as to certain claims of the '197 patent and has not yet issued an office action. '197 patent. Enzo filed a petition to terminate that second reexamination proceeding on November 16, 2022, which was denied on July 26, 2024. The PTO merged the *ex parte* reexamination proceedings as of August 2, 2024. On September 17, 2024, the PTO issued an office action, rejecting the claims subject to the merged reexamination proceedings.

Arbitration with former executives

The Company terminated the employment of Elazar Rabbani, Ph.D., the Company's former Chief Executive Officer, effective April 21, 2022. Dr. Rabbani was a **board** director of the Company until the Annual Meeting on January 31, 2024, when his term expired. Dr. Rabbani was a party to an employment agreement with the Company that entitled him to certain termination benefits, including severance pay, acceleration of vesting of share-based compensation, and continuation of benefits. Based on the terms of his employment agreement, the Company estimated and accrued a charge of \$2,600 in fiscal year 2022. The charge was partially offset by the reversal of bonus accruals. In May 2022, the Company paid Dr. Rabbani \$2,123 in severance (the payment constituted taxable income, but the Company did not withhold taxes from the payment). In July 2022, the Company paid Dr. Rabbani's income and other withholding taxes of \$1,024 related to that payment on Dr. Rabbani's behalf. **Dr. Rabbani disputed, among other things, the Company's decision to not award him a bonus for fiscal year 2021 and the amount of severance that was owed to him under his employment agreement.** On July 8, 2022, the Company filed a demand for arbitration with the American Arbitration Association (the "AAA") seeking, among other things, a declaration that the Company **has had** fully satisfied its contractual obligations to Dr. Rabbani and seeking the tax withholding reimbursement referenced above. On August 4, 2022, Dr. Rabbani filed counterclaims in the arbitration seeking, among other things, a bonus for fiscal year 2021 and additional severance that he asserted was owed to him. At the parties' joint request, the arbitration has been stayed while the parties work towards resolving the matter. A provision was made in the **consolidated** financial statements as of July 31, 2023 based on a reasonable estimate of loss; however, the actual exposure may differ.

On February 25, 2022, Barry Weiner, the Company's co-founder and President, notified the Company that he was terminating his employment as President of the Company for "Good **Reason**" **Reason,**" as defined in his employment agreement. The Company accepted Mr. Weiner's termination, effective April 19, 2022, but disagreed with Mr. Weiner's assertion regarding "Good Reason." On October 24, 2023, the Company and Mr. Weiner reached an agreement resolving the dispute, and a provision was made in the financial **consolidated** statements as of July 31, 2023 based on the settlement agreement. The Company paid Mr. Weiner \$3,600, less applicable withholding taxes, related to the agreement in November 2023.

Other Matters

On or about March 2, 2023, a **verified complaint** **Verified Complaint** was filed in the Supreme Court of the State of New York, New York County captioned Elazar Rabbani (as plaintiff) v. Mary Tagliaferri, et al. (as defendants), Index No. 651120/2023. The **verified complaint** **Verified Complaint** purports to assert causes of action for breach of fiduciary duty and corporate waste under N.Y.B.C.L. § 720, and seeks an accounting and certain injunctive relief. **Plaintiff served a copy of the verified complaint on Enzo's agent for service in New York on or about March 13, 2023.** On August 4, 2023, defendants moved to dismiss all the causes of action asserted in the **verified complaint** **Verified Complaint**. Plaintiff filed an amended complaint on or about October 4, 2023, adding, among other things, an additional cause of action for violation of N.Y.B.C.L. § 626. On October 23, 2023, **Defendants** **defendants** filed a reply in further support of their motion to dismiss. On **October 24, 2023** **November 6, 2023**, **Plaintiff** sought leave to file an opposition brief. **Defendants** **plaintiff** filed an opposition to that request on October 26, 2023. On October 31, 2023, in response to a question from the Court's law clerk, **Defendants** reiterated that they had elected to apply their original motion to dismiss to the amended pleading. On November 6, 2023, Plaintiff filed an opposition to **Defendants'** **defendants'** motion to dismiss. On November 17, 2023, **Defendants** **defendants** filed a reply brief in further support of their motion to dismiss the **Amended Complaint**. The Company cannot predict **amended complaint**. On or about July 17, 2024, the **outcome of this matter**. **Oral argument on Defendants'** **Court granted, in part, the defendants' motion to dismiss is scheduled for June 18, 2024** the amended complaint. On or about August 16, 2024, plaintiff noticed an appeal from the order granting that dismissal. On or about September 18, 2024, plaintiff filed a **Verified Second Amended Complaint**. On October 11, 2024, the defendants filed a joint stipulation and letter requesting the court to extend the deadline to respond to the Second Amended complaint from October 18, 2024 to November 18, 2024. On November 15, 2024, the plaintiff discontinued the derivative case and the related appeal (without prejudice).

On or about September 26, 2023, James G. Wolf, **Individually** **individually** and as the **Trustee** **trustee** of the Wolf Family Charitable Foundation, Barbaranne R. Wolf, Stephen Paul Wolf, and Preston M. Wolf (**collectively** the **"Petitioners"**) initiated an appraisal action against Enzo **Biochem, Inc.** in the New York Supreme Court for Suffolk County. Petitioners seek an appraisal of the value of

their shares in the Company. The amount of damages sought by the Petitioners is unspecified. On or about August 21, 2024, the Court dismissed the Company's Second and Third Affirmative Defenses. On or about September 19, 2024, the Court granted the Company permission to move for leave to reargue the Court's dismissal decision. This matter has been fully briefed by the parties. We do not anticipate a decision until sometime in the first quarter of 2025. The Company will defend itself intends to vigorously in litigate both (i) Petitioners' alleged entitlement to dissenting shareholder appraisal rights and (ii) the appraisal action, correct valuation of Petitioners' shares.

In our discontinued Clinical Labs operations, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments that we received. In April 2024, the Company engaged in settlement negotiations for a government payer and reached a verbal settlement. A provision is included The settlement was finalized in a formal written settlement agreement on August 14, 2024. The settlement resolved allegations that Enzo Clinical Labs, Inc. overbilled the Connecticut Medicaid program for testing services. The settlement was paid in August 2024 for \$1,700 to resolve the State of Connecticut's allegations and \$175 was paid to settle the whistleblowers' legal fees. On September 18, 2024, we received the unsealed complaint filed by the same whistleblowers in the financial statements based on a reasonable estimate Southern District of loss; New York ("SDNY") alleging, among other things, that the Company falsely billed Medicaid and Medicare for COVID-19 tests by utilizing inappropriate diagnostic codes to trigger payments for such tests. The SDNY advised the court that the government was not intervening in the case; however, the actual exposure private plaintiffs are still pursuing the case on the governments' behalf. The court has ordered that the matter be stayed until January 15, 2025, so that the parties may differ.

Note 14 – Departure and Appointment of Certain Officers

On September 5, 2023, the Company entered into a Separation Agreement and General Release (the "Separation Agreement") with Hamid Erfanian, the Company's Chief Executive Officer, which provides for Mr. Erfanian's separation of employment, resignations from his positions as Chief Executive Officer and as a director explore potential settlement of the Company and the payment of severance benefits as described below. Pursuant to the Separation Agreement, Mr. Erfanian's resignations as Chief Executive Officer and as a director became effective immediately and his final date of employment with the Company was November 18, 2023 (the "Separation Date").

Pursuant to the Separation Agreement, Mr. Erfanian is entitled to the following severance benefits: (i) a payment equaling twelve (12) months of his annual base salary of \$624, subject to standard payroll deductions and withholdings; (ii) a lump-sum payment of \$187, representing his annual bonus; (iii) a grant of restricted shares of the Company's common stock, par value \$0.01 per share (the "Common Stock"), in an amount equal to \$1,502 with 50% of the restricted Common Stock granted as soon as reasonably practicable after September 13, 2023, and the remaining 50% granted on the earlier of July 24, 2024 or a Change in Control of the Company (as defined in Mr. Erfanian's employment agreement with the Company); and (iv) the immediate vesting on the Separation Date of the remainder of a restricted stock unit award of 260,000 shares of Common Stock and an option to purchase 700,000 shares of Common Stock that were previously granted to Mr. Erfanian upon his employment. The foregoing are subject to continued compliance with existing restrictive covenants under Mr. Erfanian's employment agreement with the Company and his reaffirmation.

The severance benefits with respect to salary and bonus were accrued during the three months ended October 31, 2023. The share-based charges related to the immediate vesting of the remainder of the restricted stock unit award and options granted upon employment were also recognized during the three months ended October 31, 2023.

On September 5, 2023, the Company's board of directors appointed Kara Cannon, the Company's Chief Operating Officer, to serve as Interim Chief Executive Officer of the Company, which became effective immediately upon Mr. Erfanian's resignation as Chief Executive Officer. On January 31, 2024, the Company's board of directors appointed Kara Cannon as the Company's Chief Executive Officer and Patricia Eckert, CPA as the Company's Chief Financial Officer. matter.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes and other information included elsewhere in this Quarterly Report on Form 10-Q.

Forward-Looking Statements

Our disclosure and analysis in this report, including but not limited to the information discussed in this Item 2, contain forward-looking information (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended (the "Exchange Act")). All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding the Company's future financial condition, results of operations and products in research and development may include forward-looking statements. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They typically use words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "will", and other words and terms of similar meaning in connection with any discussion of future operations or financial performance. All forward-looking statements are subject to important factors, risks, uncertainties, and assumptions, including industry and economic conditions, that could cause actual results to differ materially from those described in the forward-looking statements.

Forward-looking statements may include, without limitation, statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign currency rates, intellectual property matters, the outcome of contingencies, such as legal proceedings, and future financial results. We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. As a result, investors are cautioned not to place undue reliance on any of our forward-looking statements. Investors should bear this in mind as they consider forward-looking statements. We do not assume any obligation to update or revise any forward-looking statement that we make, even if new information becomes available or other events occur in the future. We are also affected by other factors that may be identified from time to time in our filings with the Securities and Exchange Commission, some of which are set forth in Item 1A - Risk Factors in our Form 10-K filing for the **July 31, 2023** fiscal **year**, **year ended July 31, 2024**. You are advised to consult any further disclosures we make on related subjects in our periodic reports on Forms 10-Q, 8-K and 10-K filed with the Securities and Exchange Commission. Although we have attempted to provide a list of important factors which may affect our business, investors are cautioned that other factors may prove to be important in the future and could affect our operating results.

You should understand that it is not possible to predict or identify all such factors or to assess the impact of each factor or combination of factors on our business. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Overview

The **Company's** Company has operated as a life sciences company for over 45 years. The primary business of Enzo today is conducted through its Enzo Life Sciences **Products reporting unit, as described below, operates** division, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company's proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The Company monetizes its technology primarily via sales through our **one reportable segment, Products, global distribution network and licensing**. Enzo Life Sciences is a global company affected by different US **operated through the Company's wholly-owned subsidiary Enzo Life Sciences, Inc. and global economic conditions**. Our company evolved out of our core competence: the use of nucleic acids as informational molecules **its wholly-owned domestic**

and the use of compounds for immune modulation, foreign subsidiaries. Costs excluded from this reporting unit and reported as “Corporate and Other” Enzo Life Sciences financial results consist of corporate general and administrative costs which and minimal therapeutic research and development expenses. These costs are not allocable to reported within the reportable segment. Below is a brief description of this operating segment consolidated financial statements as “Corporate and Other” (see Note 12 in the Notes to Consolidated Financial Statements).

Enzo Life Sciences Products operates through the Company's wholly owned subsidiary, Enzo Life Sciences, Inc. ("Enzo Life Sciences"). It manufactures, develops and markets products and tools to life sciences, drug development and clinical research customers world-wide and has amassed a large patent and technology portfolio. Enzo Life Sciences is a recognized leader in labeling and detection technologies across research and diagnostic markets. Our strong portfolio of proteins, antibodies, peptides, small molecules, labeling probes, dyes and kits provides life science researchers tools **Statements** for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It is globally recognized and acknowledged as a leader in manufacturing, in-licensing, and commercialization of over 20,000 products. The strategic focus of this **further** segment is directed to innovative high quality research reagents and kits in the primary key research areas of genomics, immunohistochemistry, immunoassays, cellular analysis, and small molecule chemistry. The segment is an established source for a comprehensive panel of products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity and renal injury. **information**).

Discontinued operations – sale of Clinical Services business to Labcorp

Prior to July 24, 2023, we operated a clinical laboratory, doing business as Enzo Clinical Labs, which provided reference, molecular and esoteric diagnostic medical testing services in the New York, New Jersey, and Connecticut medical communities. Effective July 24, 2023, pursuant to an Asset Purchase Agreement, dated March 16, 2023 (the "Asset Purchase Agreement"), we completed the sale of certain assets used in the operation of Enzo Clinical Labs and the assignment of certain clinical lab liabilities to Laboratory Corporation of America Holdings, a Delaware corporation ("Labcorp") for an aggregate purchase price of \$113.25 million in cash, subject to customary closing adjustments (such assets and liabilities, the "clinical services business"). In connection with the sale, \$5 million of escrowed proceeds were included in prepaid and other assets as of April 30, 2024 and in other assets as of July 31, 2023 **cash**. In accordance with the sale, we ceased our clinical services operations. **Excluded from the sale of the clinical services assets were its cash and accounts receivable**. As a consequence of the sale, for the three and nine months ended April 30, 2024 and 2023 we have classified as discontinued operations all income and expenses attributable to the clinical services business. **Discontinued Operations Carve Out and Expense Allocations** business for all periods presented.

As a consequence of the sale of the clinical services business, for the three and nine months ended April 30, 2024 and 2023, results from operations for that business are classified as discontinued operations, as are its assets and liabilities as of April 30, 2024 and July 31, 2023. The carve out of the discontinued operations was prepared in accordance with the Securities and Exchange Commission's carve out rules under ASC 205-20 Discontinued Operations and is derived from identifying and carving out the specific assets, liabilities, operating expenses and interest expense associated with the clinical services business's operations. Certain administrative and overhead expenses, including personnel expenses, which were incurred by us (for which the discontinued operation benefited from such resources) are allocated out of the discontinued operations based upon the identification of those allocated expenses and to the continuing operations.

For the three and nine months ended April 30, 2023, we allocated \$527 and \$1,623, respectively of selling, general and administrative expenses from the discontinued operations to the continuing operations in the accompanying results of operations tables and explanations.

Ransomware Attack

In April 2023, the Company experienced a ransomware attack that impacted certain critical information technology systems, systems, principally of the discontinued operation. In response, we promptly deployed containment measures, including disconnecting our systems from the internet, launching an investigation with assistance from third-party cybersecurity experts, and notifying law enforcement. We adhered to our disaster recovery plan, which enabled us to maintain operations throughout the incident response process. The Company's facilities remained open, and we continued to provide services to patients and partners. We later became aware that certain data, including names, test information, and Social Security numbers, was accessed, and in some instances, exfiltrated from the Company's information technology systems as part of this incident. The investigation identified unauthorized access to or acquisition of clinical test information of approximately 2,470,000 2.5 million individuals. The Social Security numbers of approximately 600,000 of these individuals may also have been involved. Additionally, the Company has determined that some employees' information may have been involved. The Company has provided notice to the individuals whose information may have been involved, as well as to regulatory authorities, in accordance with applicable law. The Company has incurred, and may continue to incur, related expenses. The Company's cybersecurity insurance carrier is covering covered up to \$3 million of the remediation costs related to this the incident and is paying all paid service providers directly from the policy. policy proceeds.

The Company remains subject to risks and uncertainties as a result of the incident, including as a result of the data that was accessed or exfiltrated from the Company's network as noted above. Additionally, security and privacy incidents have led to, and may continue to lead to, additional regulatory scrutiny and class action litigation exposure. We are in the process of evaluating the full scope of the costs and related impacts of this incident. See Note 13 of the consolidated financial statements for discussion of litigation in connection with this incident.

Results of Operations from Continuing Operations
Three months ended April 30, 2024 October 31, 2024 compared to April 30, 2023 October 31, 2023
(in \$000s)

Comparative Financial Data from Continuing Operations for the three months ended April 30, October 31,

	2024	2023	Favorable (Unfavorable)	% Change	2024	2023	Favorable (Unfavorable)	% Change
Revenues	\$ 8,022	\$ 7,485	\$ 537	7	\$ 6,213	\$ 7,806	\$ (1,593)	(20)
<u>Operating costs and expenses:</u>								
Cost of revenues	4,289	4,476	187	4	3,681	4,351	670	15
Cost of revenues – inventory provision					252	—	(252)	**
Research and development	605	884	279	32	562	849	287	34
Selling, general and administrative	4,479	6,212	1,733	28	4,882	7,007	2,125	30
Legal and related expenses	692	4,265	3,573	84	458	1,075	617	57
Total operating costs and expenses	10,065	15,837	5,772	36	9,835	13,282	3,447	26
Operating loss	(2,043)	(8,352)	6,309	76	(3,622)	(5,476)	1,854	34
<u>Other income (expense):</u>								
Interest, net	726	(36)	762	**	620	977	(357)	(37)
Fair value adjustment	(384)	—	(384)	**	—	(328)	328	100
Other	94	144	(50)	(34)	123	158	(35)	(22)
Foreign exchange (loss) gain	(524)	347	(871)	**				
Foreign exchange loss					(192)	(1,006)	814	81
Loss before income taxes	\$ (2,131)	\$ (7,897)	\$ 5,766	73	\$ (3,071)	\$ (5,675)	\$ 2,604	46

**** not meaningful**

Consolidated Results:

The “2024 period” and the “2023 period” refer to the three months ended April 30, 2024 October 31, 2024 and April 30, 2023, 2023, respectively.

Product revenues Revenues were \$8.0 million \$6.2 million in the 2024 period and \$7.5 million \$7.8 million in the 2023 period, an increase a decrease of approximately \$0.5 million \$1.6 million or 7%. During 20% due to a reduction in orders from certain large customers in the clinical market in the comparable periods and a large order from an industrial customer in the 2023 period which was not repeated in the 2024 period, period. Overall, we experienced a 40% increase decline in revenues in European markets, driven by an increase all geographic areas of our customer base due to declining market demand related to general continued headwinds in the marketing effort in drug development product sales and a 15% increase in revenues in the Asia Pacific market. These increases were partially offset by a slight decrease in revenues from the US market period over period. life sciences tools space.

The cost of Product revenues was \$4.3 million \$3.7 million in the 2024 period and \$4.5 million \$4.4 million in the 2023 period, a decrease of \$0.2 million \$0.7 million or 4%. 15% due to lower revenues. The gross profit margin for Products was approximately 47% 41% and 44% in the 2024 period and 40% in the 2023 period, periods, respectively. The 2024 period was negatively impacted by inventory disposals due to a portfolio optimization initiative. The 2023 period gross profit was positively impacted by the a decrease in manufacturing headcount, other cost containment measures, and a more positive profitable mix of the types of products sold and lower input costs. The 2023 period was negatively impacted by the impact of inflation on materials cost and market adjustment salary increases. sold.

The cost of revenues – inventory provision was \$0.3 million for raw material inventory we intended to use in manufacturing and sell to laboratory customers which we fully reserved in the 2024 period. This expense represents 4% of the period's revenues.

Research and development expenses were \$0.6 million \$0.5 million in the 2024 period and \$0.9 million \$0.8 million in the 2023 period, a decrease of \$0.3 million or 32% 34%. Throughout There was an emphasis on manufacturing effort in the 2024 period. During the 2023 period there were no was a greater investment in research and development activities pertaining to translational research due to our exiting the clinical reference business at the end of fiscal 2023, resources and materials consumed.

Selling, general and administrative expenses were \$4.5 million \$4.9 million during the 2024 period versus \$6.2 million \$7.0 million during the 2023 period, a decrease of \$1.7 million \$2.1 million or 28% 30%. The Corporate and Other segment expense decreased \$1.5 million \$2.2 million during the 2024 period primarily due to the consulting severance provisions and other professional fees accelerated recognition of share-based compensation incurred in during the 2023 period of approximately \$1.5 million related to a former senior officer. The remainder of the Asset Purchase Agreement (as defined above), a revolving credit facility, decrease in the ransomware attack, and 2024 period is due to lower salaries and share based compensation for our senior directors and officers and lower bonus accruals. The Products segment expense in the 2024 period, period increased \$0.1 million compared to 2023 period due to investments in sales and marketing.

Legal and related expenses were \$0.7 million \$0.5 million during the 2024 period and \$4.3 million \$1.1 million in the 2023 period, a decrease of \$3.6 million \$0.6 million or 84% 57%. During the 2023 period, we required significant significantly more legal expertise and assistance associated with the ransomware attack and matters related to the Asset Purchase Agreement, a revolving credit facility, the ransomware attack, the Debentures, and matters relating to arbitrations with two former senior executives, executives' arbitration, one of which was settled during the 2024 2023 period and one of which is ongoing.

Interest income, net was \$0.7 million \$0.6 million in the 2024 period compared to \$0.1 interest expense \$1.0 million in the 2023 period, a favorable variance decrease of \$0.8 million. The 2024 period's interest income was earned on \$0.4 million or 37% due to a decrease in the net proceeds from the Asset Purchase Agreement, which are on deposit balance of cash held in a money market fund. In the 2024 period we incurred interest expense on the Debentures which partially offset some of account and a decline in the interest income. In the 2023 period, we rate earned some interest in a money market fund which was offset by interest expense, primarily on a mortgage and a revolving credit facility, due to Federal Reserve actions to lower discount rates.

We recorded a fair value adjustment charge of approximately \$0.4 million \$0.3 million for the Debentures based on their fair value as of April 30, 2024 October 31, 2023, which were due and fully repaid in May 2024.

Other income in both periods is primarily from the subletting of a portion of our office space in New York, NY.

The foreign exchange loss recognized by the Products segment during the 2024 period was \$0.5 million \$0.2 million compared to gain of \$0.4 million in the 2023 period, an unfavorable variance of \$0.9 million.

The foreign exchange revaluation loss in the 2024 period was primarily due to the appreciation of the U.S. dollar versus the Swiss franc as at the end of the period compared to its start and the negative impact that had when the Swiss operating entity's U.S dollar liabilities were revalued into Swiss francs. The gain during the 2023 period was due to the depreciation of U.S. dollar versus the Swiss franc and British pound as of the end of that period compared to its start and the positive impact that had when the Swiss operating entity's U.S dollar liabilities were revalued into Swiss francs and when certain British pound denominated assets were revalued into U.S. dollars.

Results of Operations from Continuing Operations
Nine months ended April 30, 2024 compared to April 30, 2023
(in \$000s)

Comparative Financial Data from Continuing Operations for the nine months ended April 30,

	2024	2023	Favorable (Unfavorable)	% Change
Revenues	\$ 24,381	\$ 22,102	\$ 2,279	10
<u>Operating costs and expenses:</u>				
Cost of revenues	12,969	13,681	712	5
Research and development	2,035	2,708	673	25
Selling, general and administrative	16,550	17,078	528	3
Legal and related expenses	2,527	6,160	3,633	59
Total operating costs and expenses	<u>34,081</u>	<u>39,627</u>	<u>5,546</u>	14
Operating loss	(9,700)	(17,525)	7,825	45
<u>Other income (expense):</u>				
Interest, net	2,595	99	2,496	**
Fair value adjustment	(1,095)	—	(1,095)	**
Other	373	262	111	42
Foreign exchange (loss) gain	(842)	1,022	(1,864)	**
Loss before income taxes	<u>\$ (8,669)</u>	<u>\$ (16,142)</u>	<u>\$ 7,473</u>	46

**** not meaningful**

Consolidated Results:

The “2024 period” and the “2023 period” refer to the nine months ended April 30, 2024 and April 30, 2023, respectively.

Product revenues were \$24.4 million in the 2024 period and \$22.1 million in the 2023 period, an increase of approximately \$2.3 million or 10%. During the 2024 period, we experienced a 10% increase in the US market, a 16% increase in the European market, and a 2% increase in the Asia Pacific market. The increase in revenues was driven by an increase in the marketing effort in drug development and cell and gene therapy markets.

The cost of Product revenues was \$13.0 million in the 2024 period and \$13.7 million in the 2023 period, a decrease of \$0.7 million or 5%. The gross profit margin for Products was approximately 47% in the 2024 period and 38% in the 2023 period. The 2024 period gross profit was positively impacted by the more profitable mix of the types of products sold, higher revenues sourced from the US market, and lower input costs. The 2023 period was negatively impacted by the impact of inflation on materials cost and market adjustment salary increases.

Research and development expenses were \$2.0 million in the 2024 period and \$2.7 million in the 2023 period, a decrease of \$0.7 million or 25%. As of the start of the 2024 period, we had ended our research and development activities into translation products due to our exiting the clinical reference business.

Selling, general and administrative expenses were \$16.6 million during the 2024 period versus \$17.1 million during the 2023 period, a decrease of \$0.5 million or 3%. The Corporate and Other segment expense decreased \$0.8 million during the 2024 period primarily due to the consulting and other professional fees incurred in the 2023 period related to the Asset Purchase Agreement, a revolving credit facility, the ransomware attack, and lower salaries and share based compensation for our senior officers in the 2024 period. The Products segment expense in the 2024 period increased approximately \$0.3 million compared to the 2023 period due to investments in information technology and sales and marketing.

Legal and related expenses were \$2.5 million during the 2024 period and \$6.2 million in the 2023 period, a decrease of \$3.6 million or 59%. During the 2023 period, we required significant legal expertise and assistance associated with matters related to the Asset Purchase Agreement, a credit facility, the ransomware attack, the convertible debentures, and matters relating to arbitrations with two former senior executives, one of which was settled during the 2024 period and one of which is ongoing. Interest income, net was \$2.6 million in the 2024 period and \$0.1 million \$1.0 million in the 2023 period, a favorable variance of \$2.5 million \$0.8 million. The 2024 period's interest income was earned on the net proceeds from the Asset Purchase Agreement, which are on deposit in a money market fund. In the 2024 period we incurred interest expense on the Debentures which partially offset some of the interest income. In the 2023 period, we earned some interest in a money market fund which was offset by interest expense, primarily on a mortgage and a revolving credit facility. During the 2024 period we recorded a fair value adjustment charge of approximately \$1.1 million for the Debentures based on their fair value as of April 30, 2024, which were due and fully repaid in May 2024. Other income in both periods is primarily from the subletting of a portion of our office space in New York, NY.

The foreign exchange loss recognized by the Products segment during the 2024 period was approximately (\$0.9) million compared to gain of \$1.0 million in the 2023 period, an unfavorable variance of \$1.9 million. The foreign exchange revaluation loss in the 2024 period was primarily due to the revaluation of intercompany balances denominated in European currencies into Swiss francs, which appreciated slightly, by our Swiss subsidiary. The 2023 period revaluation loss was due to significant depreciation of the Swiss franc, versus the Great Euro and British pound and Euro as at the end of the period compared to its start and the negative impact that had U.S dollar, when the Swiss operating entity's pound and Euro receivables intercompany balances were revalued into Swiss francs. The gain during the 2023 period was due to the depreciation of higher, especially those denominated in the U.S. dollar versus the British pound and Swiss franc as of the end of that period compared to its start and the positive impact that had when revaluing certain British pound denominated assets and the Swiss operating entity's U.S. dollar liabilities into U.S. dollars. dollar.

Liquidity and Capital Resources

Our aggregate cash and cash equivalents and restricted cash as of April 30, 2024 October 31, 2024 was \$47.7 million and July 31, 2023 was \$57.2 million and \$83.4 million, respectively. Our working capital was \$54.1 million and \$58.5 million \$52.3 million as of April 30, 2024 and July 31, 2023, respectively. July 31, 2024. The decrease of \$26.2 million \$4.6 million in our cash and cash equivalents and restricted cash balance as of April 30, 2024 October 31, 2024 was primarily due to the period net loss and by cash used to pay down accounts payable – trade and accrued liabilities, particularly those of the discontinued operations. operations, partially offset by the release from escrow of \$5.0 million, as discussed below. Based on the current available working capital, management believes the Company has sufficient funds to meet its operating requirements for at least the next twelve months from the date of the filing of this report. Our working capital was \$36.3 million and \$45.2 million as of October 31, 2024 and July 31, 2024, respectively.

Net cash used in operating activities during the 2024 period was \$25.2 million \$9.0 million, compared to \$19.9 million \$13.4 million during the 2023 period, an unfavorable a favorable variance of \$5.3 million \$4.4 million, due to the paydown of accounts payable – trade and accrued liabilities smaller net loss from continuing operations in the 2024 period.

Net cash provided by investing activities during the 2024 period was approximately \$4.6 million and represents the release of cash held in escrow from the Labcorp Asset Purchase Agreement which closed in July 2023, partially offset by capital expenditures. Net cash used in investing activities during the 2024 and 2023 period was approximately \$0.4 million and \$2.2 million, respectively and represents \$0.3 million for capital expenditures.

Net cash used in financing activities in the 2024 period and 2023 periods amounted to \$0.6 \$0.2 million and \$0.5 million primarily represents cash payments for withholding taxes on bonuses paid in stock. Net cash provided by financing activities in the 2023 period primarily represents net proceeds from borrowings under a revolving credit agreement.

The Company is a defendant in a number of legal matters, including class action lawsuits related to the ransomware attack of its information technology systems which occurred in April 2023. We face a significant risk due to ongoing litigation that has the potential to result in future financial obligations, adversely impacting the Company's business and profitability.

Management is not aware of any other trends, events or uncertainties that have or are reasonably likely to have a material negative impact upon our (i) short-term or long-term liquidity, or (ii) net sales or income from continuing operations. Our business is subject to seasonal variations thereby impacting our liquidity and working capital during the course of our fiscal year. To the extent that we do not generate sufficient cash from operations, our cash balances will decline. We may also use our cash to explore and/or acquire new product technologies, applications, product line extensions, or other new business opportunities. In the event that our available cash is insufficient to support such initiatives, we may need to incur indebtedness or issue Common Stock to finance plans for growth. Volatility in the credit markets and the liquidity of major financial institutions may have an adverse effect on our ability to fund our business strategy through borrowings in the public or private markets on terms that we believe to be reasonable, if at all.

Labcorp Asset Purchase Agreement and release of Cash in Escrow

We have had indemnification obligations to Labcorp under the Asset Purchase Agreement that may require could have required us to make future payments to Labcorp and other related persons for any damages incurred by Labcorp or such related persons as a result of any breaches of our representations, warranties, covenants or agreements contained in the Asset Purchase Agreement, or arising from the Retained Liabilities (as such term is defined in the Asset Purchase Agreement) retained liabilities or certain third-party claims specified in the Asset Purchase Agreement. Generally, our representations and warranties survive survived for a period of 15 months from the closing date, which was July 24, 2023, other than certain fundamental representations, which survive until the expiration of the applicable statute of limitations. There is an indemnification cap with respect to a majority of the Company's indemnification obligations under the Asset Purchase Agreement with the exception of claims for actual fraud, the breach of any fundamental representations and certain other items, which are subject to a higher indemnification cap (up to the purchase price). Pursuant to the terms of the Asset Purchase Agreement, we, Labcorp, and an escrow agent entered into an Escrow Agreement at closing, pursuant to which Labcorp deposited \$5 million of the aggregate purchase price of the clinical service business into an escrow account established with the Escrow Agent in order to satisfy, in whole or in part, certain of our indemnity obligations, if any, that arise arose under the Asset Purchase Agreement. If, on Labcorp made no claims and required only a reimbursement of certain legal fees it had incurred, which were immaterial. On October 30, 2024, the 15-month anniversary escrowed funds of the closing date, there are funds remaining in the escrow account, the Escrow Agent will release any funds remaining in the escrow account to us minus any amounts being reserved for escrow claims asserted by Labcorp prior to such date. Upon the resolution of any pending escrow claims, the Escrow Agent will, within two business days of receipt of joint instructions or a final order from a court (as described in the Escrow Agreement) disburse such reserved amount \$5.0 million were released to the parties entitled to such funds. Through the date Company and are included in cash and cash equivalents as of this filing, no material escrow claims with respect to indemnity obligations have been asserted.

October 31, 2024.

Off Balance Sheet Arrangements

The Company does not have any "off-balance sheet arrangements" as such term is described in Item 303(a)(4) 303 of Regulation S-K.

General and estimates

The Company's discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc.'s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. U.S. GAAP. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and judgments also affect related disclosure of contingent assets and liabilities.

On an on-going basis, we evaluate our estimates, including those related to contractual expense, allowance for expected credit losses, inventory, and income taxes. The Company bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Contingencies

Contingencies are evaluated and a liability is recorded when the matter is both probable and reasonably estimable. Gain contingencies are evaluated and not recognized until the gain is realizable or realized.

Product revenues

Products revenues consist of the sale of single-use products used in the identification of genomic information and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Any claims for credit or return of goods may be made generally within 30 days of receipt. Revenues are reduced to reflect estimated credits and returns, although historically these adjustments have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products.

Accounts Receivable

Accounts receivable are reported at realizable value, net of expected credit losses, which is estimated and recorded in the period of the related revenue.

As of April 30, 2024, October 31, 2024 and July 31, 2023, July 31, 2024, Products accounts receivable, net were \$3,935, \$3,842 and \$4,808, \$3,988, respectively. As of April 30, 2024, October 31, 2024 and July 31, 2023, July 31, 2024, these totals include foreign receivables, net, of \$1,276, \$847 and \$1,277, \$1,185, respectively.

Income Taxes

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It is the Company's policy to provide for uncertain tax positions, if any, and the related interest and penalties based upon management's assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company's effective tax rate in a given financial statement period may be affected.

Inventory

The Company values inventory at the lower of cost (first-in, first-out) or net realizable value. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to net realizable value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations.

Long-Lived Assets

The Company reviews the recoverability of the carrying value of long-lived depreciable assets of an asset or asset group for impairment if indicators of potential impairment exist. Should indicators of impairment exist, the carrying values of the depreciable assets are evaluated in relation to the operating performance and future undiscounted cash flows of an asset or asset group. The net book value of the depreciable long lived asset is adjusted to fair value if its expected future undiscounted cash flow is less than its book value.

During the three and nine months ended April 30, 2024, October 31, 2024 and 2023 there was no impairment of depreciable long-lived assets used in continuing operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company's management conducted an evaluation (as required under Rules 13a-15(b) and 15d-15(b) under the Exchange Act) of the Company's "disclosure controls and procedures" (as such term is defined under the Exchange Act), under the supervision and with the participation of each of our principal executive officer and principal financial officer. Based on this the evaluation as a result of the material weakness identified below, the our Disclosure Controls, our principal executive officer and the principal financial officer have concluded that, the Company's disclosure controls and procedures were not effective as of the end of the period covered by this report.

As previously disclosed on Current Reports on Form 8-K dated April 13, 2023, October 31, 2024, and May 30, 2023, respectively, the Company experienced a ransomware attack that impacted certain critical information technology systems. In response, the Company promptly deployed containment measures, including disconnecting its systems from the internet, launching an investigation with assistance from third-party cybersecurity experts, and notifying law enforcement. The Company adhered to its disaster recovery plan, which enabled it to substantially maintain operations throughout the incident response process.

As a result of the ransomware attack and the subsequent investigation, the Company determined a material weakness existed that impaired the Company's ability our Disclosure Controls were effective to ensure that standard systems information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and accounting processes could operate effectively. As a result, a reasonable possibility exists that a material misstatement of reported within the Company's annual or interim financial statements would not be prevented or detected time periods specified in the SEC's rules and corrected in a timely manner. The following forms and is a description of the material weakness identified:

Control Environment, Risk Assessment, Information accumulated and Communication, and Control Activities

We did not maintain effective internal control related communicated to our control environment, risk assessment, information management, including our principal executive officer and communication, and control activities:

- In April 2023, we became aware that we were exposed to a ransomware attack in our Information Technology environment which interrupted systems and affected operations. The effect of these circumstances significantly impacted the following:
 - our ability to access and reinstate our financial systems for an extended period to a new normal state of operation;
 - the need to rebuild our financial information from backups as a result of the ransomware attack;
 - additional workload associated with process workflows that were previously automated but were manually performed as a result of the ransomware attack.
- We were required to supplement resources and as a result, did not adequately perform in a timely manner the following:
 - assessment, redesign and timely evaluation of performance of controls over financial reporting risks as a result of existing IT circumstances; and
 - generate real time information across the organization to allow the finance department to perform timely application of controls; and
 - Internal controls over financial reporting related to the recording and processing of revenue transactions could not be completed timely using standard methods due to the limitations of access to data.

Management began remediation measures during and after the April 30, 2023 period end which were substantially implemented by July 31, 2023. During the nine months of the fiscal year ending July 31, 2024, evaluation of certain controls' effectiveness could not be performed according principal financial officer, as appropriate to the typical frequency or sufficient evidence of control performance was not available for testing due to the cyber incident. allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

Management assessed the effectiveness of our internal control over financial reporting as of April 30, 2024. In making this assessment, management used the criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this assessment, management has concluded that, as of April 30, 2024, our internal control over financial reporting was not effective because the nine months of the period included timeframes during which specific data was not available for testing.

Except as otherwise described above, there was There were no change changes in our internal control over financial reporting that occurred during the third quarter of fiscal 2024 period ended October 31, 2024 that has have materially affected, or is are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

There have been no other material developments with respect to previously reported legal proceedings discussed in the annual report on Form 10-K ~~as amended~~ for the fiscal year ended ~~July 31, 2023~~ July 31, 2024 filed with the Securities and Exchange Commission, other than as noted in Note 13 to ~~the these~~ Consolidated Financial Statements as of ~~April 30, 2024, which is incorporated herein by reference,~~ October 31, 2024.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in Part 1, Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended ~~July 31, 2023~~ July 31, 2024.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other ~~Information~~ Information00

None.

Item 6. Exhibits

Exhibit No.	Exhibit
-------------	---------

31.1	Certification of Kara Cannon pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Patricia Eckert pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Kara Cannon pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Patricia Eckert pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101. INS*	Inline XBRL Instance Document.
101. SCH*	Inline XBRL Taxonomy Extension Schema Document.

101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* XBRL (Extensible Business Reporting Language) information is being furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ENZO BIOCHEM, INC.
(Registrant)

Date: June 13, 2024 December 16, 2024

by: /s/ Patricia Eckert

Chief Financial Officer and
Principal Accounting Officer

35

27

Exhibit EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kara Cannon, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Enzo Biochem, Inc. (the “registrant”).
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

- (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 13, 2024 December 16, 2024

By: /s/ Kara Cannon

Kara Cannon
Chief Executive Officer

Exhibit EXHIBIT 31.2

**CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Patricia Eckert, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of Enzo Biochem, Inc. (the "registrant").
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **June 13, 2024** **December 16, 2024**

By: /s/ Patricia Eckert

Patricia Eckert

Chief Financial Officer and Principal
Accounting Officer

Exhibit EXHIBIT 32.1

**CERTIFICATION PURSUANT TO
TITLE 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Enzo Biochem, Inc., and Subsidiaries ("the Company") on Form 10-Q for the period ended **April 30, 2024** **October 31, 2024** as filed with the Securities and Exchange Commission on the date hereof the "Report"), I, Kara Cannon, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: June 13, 2024 December 16, 2024

By: /s/ Kara Cannon

Kara Cannon

Chief Executive Officer

Exhibit EXHIBIT 32.2

**CERTIFICATION PURSUANT TO
TITLE 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-Q for the period ended April 30, 2024 October 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Patricia Eckert, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: June 13, 2024 December 16, 2024

By: /s/ Patricia Eckert

Patricia Eckert

Chief Financial Officer and Principal
Accounting Officer

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.